

Prof. Andrea Calcagno



Current position Since October 2020, Associate Professor of Infectious Diseases in the Department of Translational Medicine, University of Eastern Piedmont (Novara, Italy).

Education I Graduated with honors at the post-graduate School of Infectious Diseases and Tropical Medicine of the University of Turin (Turin, Italy) with a dissertation on the pharmacogenetics of nevirapine in people with HIV.

I Received the Diploma in Tropical Medicine & Hygiene (DTM&H) at Mahidol University, (Bangkok, Thailand) in 2006.

In 2004, I Graduated with honors in Medicine and Surgery at the University of Turin (Turin, Italy) with a dissertation on antibiotic resistance in Intensive Care Units.

In August 2003, I spent one month as a trainee at the Internal Medicine ward of the University Hospital in Khartoum (Khartoum, Sudan).

In the academic year 2001/2, I attended the fourth year of my Medical training at the University of Cordoba (Cordoba, Spain).

Working Experience - Clinical Since October 2025 I have been working as Infectious Diseases Consultant at the “Maggiore della Carità” Hospital (Novara, Italy).

In the years 2008-2020, I have been working as Infectious Diseases Consultant at the “Amedeo di Savoia” Hospital (ASL TO2 and then ASL “Città di Torino”, Turin, Italy).

I have been mostly working in the inpatient ward taking care of patients with different infections including immune-compromised hosts (with expertise in patients with HIV/AIDS), patients with COVID-19, and tropical diseases. Since 2020, I have been involved in Infectious Diseases consultation in 8 other hospitals including internal medicine, surgical, intensive care, and onco-hematological wards. I am currently in charge of a multidisciplinary outpatient service for patients with non-tuberculous mycobacteria infections. In the last two years, I opened a referral outpatient consultation for orthopedic infections (once a week).

I spent six months (October 2006 – April 2007) and then one month (February 2009) in a rural hospital in Kiremba (Burundi) as responsible for the Pediatric and Malnourished children ward (50 beds) and of the HIV clinic.

Since 2003, I am registered at the Turin Medical Board of Physicians and Surgeons (License number 20030).

Teaching and Academic Experience I have been Research Fellow (March 2008 - March 2012), temporary Assistant Professor (October 2012 - September 2020) and Associated Professor (October 2020 – September 2025) at the Unit of Infectious Diseases, Department of Medical Sciences, University of Turin (Turin, Italy).

Since 2013/2014, I have been responsible for the Infectious Diseases course at the Nursing School (3 courses) and, since the academic year 2017/2018, co-responsible of the Infectious Disease course at the School of Medicine and Surgery of the University of Turin. The courses for students in Medicine and Surgery have been held at the San Luigi Hospital (in English) and at the Città della Salute e della Scienza (in Italian), in Turin (Italy).

Since 2012, I have been teaching in the post-graduate school in Infectious Diseases and Tropical Medicine at the University of Turin (Turin, Italy).

Since the academic year 2021/2022 I have been teaching in the PhD Programme in Experimental Medicine and Therapy, University of Turin (Turin, Italy).

I have been teaching on HIV/AIDS in Luanda (Angola) in the years 2022, 2023 and 2024 following a collaborative project led by the IRCCS Negrar (Verona, Italy).

**Research
experience and
interests**

I have been working in a group with internationally recognized expertise in the pharmacology of antiretrovirals; we gradually expanded our interests and research activities in the field of pharmacokinetics and pharmacogenetics of antibiotic, antifungal and antitubercular drugs.

I developed my personal research focus on the central nervous system complication of HIV and other viral infections by creating an internal group and external collaborations with neurologists, neuropsychologists, and radiologists and by enhancing the capacity of our research lab (in terms of biomarker analysis and development). I am also one of the founders of the GEPPPO multicenter and multidisciplinary cohort that studies ageing in people with and without HIV.

In the last three years, I helped create collaborations with pulmonologists (on tuberculosis and NTM infections), orthopedics (on prosthetic joint infections), microbiologists (on gut microbiome and cerebrospinal fluid virome), and with veterinary doctors (on vector-borne zoonosis): studies in these fields are currently ongoing.

I have been a sub-investigator and principal investigator of phase II, III, and independent trials in the fields of HIV, tuberculosis, NTM, and COVID-19.

Fund Raising

I raised a total of approximately 690k euros from public funding (Italian Ministry of Health and University of Turin), Private Companies' international calls and support to investigator-initiated studies.

PhD Committee

I was part of PhD Committees for the University of Liverpool (UK), University of Basel (Switzerland) and University of Cordoba (Spain).

Appointments

I was a Member of the Governing Council of the Italian Society of Infectious Diseases and Tropical Medicine (SIMIT) in the years 2015-2019.

**Editorial and
Society/Study
Group Board**

Since 2013, Associate Editor of “BMC Infectious Diseases” Journal. Since 2015, Vice Editor of “Infectious Diseases and Tropical Medicine” and Associate Editor of “Le Infezioni in Medicina. Since 2018, Academic Editor of “PlosOne”.

Since 2015, in the Scientific Committee of the ICONA foundation (Italian Cohort Naïve Antiretrovirals). Since 2015 member of the GEPPPO (GEriatric Patients living with HIV/AIDS: a Prospective Multidimensional cOhort) Study Group and, since 2017, in the Scientific Board of the cohort. Since 2017 in the Scientific Committee of “IRENE” (Italian Registry of Pulmonary Non-Tubercular Mycobacteria). Since 2022 member of the Scientific Committee of StopTB Italia.

Since 2017, I have been the Coordinator of the Study group on Mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine (SIMIT).

**Conference
Organization**

I have been a Member of the Organizing Committee of the International “Antivirals PK Workshop” 2018-2023 and I am now in the Scientific Committee of the Workshop.

I have been a member of the Scientific Committee of the Italian Conference on AIDS and Antiviral Research in the years 2013 and (2016 to 2025).

Since 2018 I have been in the Scientific Committee of the Residential Course on the Clinical Pharmacology of Antivirals, held every year in January in Turin.

ESCMID research grant and conference abstract reviewer since 2020.

Guidelines

I have been a member of the HIV/AIDS expert Panel writing the Italian Guidelines on the use of antiretroviral drugs and on the management of HIV-positive patients (from 2012 until 2017, when the last version was released).

Committees

Since 2021, I have been a member of the Regional Committees (Piedmont, Italy) on Antimicrobial Resistance (PP10) and prevention of Infectious Diseases (PL14).

**National and
International
Collaborations**

Since 2014, I helped building a research collaboration with the Infectious Disease Institute, Makerere University (Kampala, Uganda): the main topics were the capacity building of laboratory facilities and conduction of phase IV studies.

I personally received three Erasmus+ projects (in collaboration with the Department of Social Sciences) for the years 2019-2022, 2020-2023, and 2022-2025 for promoting the exchange between the University of Torino and the Makerere University (Teachers and third-grade students exchange). Since 2020 we have been organizing the ToAfrica Summer School (<https://www.toafrica.it>).

Several collaborations are currently ongoing in Italy and Europe (specifically in centers in the United Kingdom, Spain, and France). A research and tutoring collaboration is ongoing with the University of California at San Diego (UCSD, Prof. Scott Letendre). An ongoing clinical and reaserch collaboration between our Unit, an NGO (Idea onlus), and a rural hospital in North Uganda (Kalongo Hospital) has been created and it is still ongoing.

Awards

- Winner of the "ICAR CROI Award" in the years 2012, 2013, 2014, 2015 and 2016.
- Winner of the special jury "ICAR CROI Award 2017" for young Italian researchers for the project entitled "Discordant HIV RNA in Olfactory Mucosa of HIV-positive Patients" (Calcagno A, et al. 24th Conference on Retroviruses and Opportunistic Infections, February 13-16, 2017, Seattle, WA, USA. P379).

Orcid ID 0000-0003-2534-8815

Publications

1. Vada R, Zanet S, Trisciuglio A, Varzandi AR, [Calcagno A](#), Ferroglio E. A one-health approach to surveillance of tick-borne pathogens across different host groups. **BMC Vet Res.** 2025.
2. Fumagalli G, Mencarini J, Sini I, Allavena L, Tadolini M, Mantero M, Blasi F, Riccardi N, Pontarelli A, Piccioni P, [Calcagno A](#), Sotgiu G, Shah D, Codecasa LR, Parrella R; StopTB Italia ODV. Post-tuberculosis lung disease: a guide for clinicians. **Infection.** 2025.
3. Milic J, Calza S, Lazzarini L, Cocchi M, Motta F, Renzetti S, Sighinolfi L, Belli M, Todisco V, Albertini M, Gallerani A, Menozzi M, Cuomo G, Mancini G, Mussi C, Mussini C, [Calcagno A](#), Guaraldi G. Prevalence and risk factors of cognitive frailty in people with HIV. **AIDS.** 2025.
4. Mainardi I, Gerevini S, Tarantino A, Vercesi R, Catalano G, Garcia Martearena MDC, Negri M, Vezzulli P, Bestetti A, Moiola L, Boschini A, [Calcagno A](#), Del Bono L, Gallo A, Mena M, Moiola MC, Castagna A, Filippi M, Lazzarin A, Cinque P; PML Study Group. Changing clinical and laboratory characteristics of Progressive Multifocal Leukoencephalopathy: a retrospective national cohort study. **Clin Infect Dis.** 2025.
5. Manca A, [Calcagno A](#), D'Avolio A, Cusato J. Pharmacogenetics of First-Line Antitubercular Drugs: An Update. **Ther Drug Monit.** 2025.
6. Longo BM, Bigliano P, Libanore V, Fontana S, Ranzani FA, Cabutti F, Ricci D, Feyles E, Scarso S, Angheben A, Brusa MT, Gobbi F, [Calcagno A](#). Loiasis presenting as monolateral cervical lymphadenopathy. **J Travel Med.** 2025.
7. [Calcagno A](#), Carola L, Barbara R, Marco M, Andrea P, Roberto A, Francesca R, Roberta B, Tiziano A, Carmelina C, Giulia G, Mattia T, Giovanni DP, Stefano B. Full reservoirs and poor adherence: two cases of symptomatic HIV cerebrospinal fluid escape with tenofovir alafenamide/emtricitabine/bictegravir. **AIDS.** 2025.
8. Palermi A, De Nicolò A, Antonucci M, Soloperto S, Billi M, Manca A, Cusato J, Menegatti G, Lamorde M, [Calcagno A](#), Waitt C, D'Avolio A. A Novel HPLC-MS/MS Method for the Intracellular Quantification of the Active Triphosphate Metabolite of Remdesivir: GS-443902. **J Xenobiot.** 2025.
9. Winston A, [Calcagno A](#), Cinque P. Cognitive impairment in persons with HIV: changing aetiologies and management strategies. **Curr Opin HIV AIDS.** 2025.
10. Kuksa L, Andrejak C, Haecker B, Bothamley G, [Calcagno A](#), Cirillo DM, Duarte R, Fatima R, Ferlazzo G, Guglielmetti L, Günther G, Hewison C, Horsburgh CR, Jäger T, Kalancha Y, Otto-Knapp R, Kranzer K, Lillebaek T, Marks G, Middelkoop K, Motta I, Rabinova V, Sommerfeld P, Tettevin P, Lange C. Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy. **IJTD Open.** 2025.
11. Imperiale D, Atzori C, Angeloro DP, Murgioni A, Bagatin A, Secci V, [Calcagno A](#), Capobianco M, Coletti Moja M, Rota E, Bongioanni MR, Rosso M, Godi L, Barra M, De Mattei M, Bonzanino M, Ferrandi D, Rainero I, Lopiano L, Bozzali M. Real-life reliability of plasma pTau181, Aβ₄₂/Aβ₄₀, and pTau181/Aβ₄₂ measured by Lumipulse G600II in predicting cerebrospinal fluid amyloid status. **J Alzheimers Dis.** 2025.
12. Matteelli A, Formenti B, Cimaglia C, Visconti M, di Rosario G, Russo G, [Calcagno A](#), Gori A, Coppola N, Francisci D, Andreoni M, Foti G, Cristini F, Bassi P, Luzzati R, Scaggiante R, Torti C, Lapadula G, Cuzzi G, Antinori A, Gagliardini R, Navarra A, Girardi E, Goletti D. Cascade of care for TB infection in persons newly diagnosed with HIV in Italy. **Int J Tuberc Lung Dis.** 2024.
13. [Calcagno A](#), Pizzi C, Pocongo B, Ronzoni N, Alladio F, Francisco NM, Kalume A, Di Perri G, Gobbi F. Factors Associated with HIV Viral Suppression in People Followed in an Outpatient Clinic in Angola During and After the COVID-19 Pandemic. **AIDS Patient Care STDS.** 2024 Oct 4. doi: 10.1089/apc.2024.0175. Epub ahead of print. PMID: 39364627.
14. Kincer LP, Dravid A, Trunfio M, [Calcagno A](#), Zhou S, Vercesi R, Spudich S, Gisslen M, Price RW, Cinque P, Joseph SB. Neurosymptomatic HIV-1 CSF escape is associated with replication in CNS T cells and inflammation. **J Clin Invest.** 2024 Oct 1;134(19):e176358. doi: 10.1172/JCI176358. PMID: 39352388; PMCID: PMC11444166.
15. Stroffolini G, Atzori C, Imperiale D, Trunfio M, Di Perri G, [Calcagno A](#). Central Nervous System Disorders with Auto-Antibodies in People Living with HIV. **Microorganisms.** 2024 Aug 24;12(9):1758. doi: 10.3390/microorganisms12091758. PMID: 39338433; PMCID: PMC11433650.
16. Riccardi N, Monari C, Antonello RM, Saderi L, Occhineri S, Pontarelli A, Zucchi P, Buonsenso D, Falbo E, Faverio P, Aliberti S, Parrella R, Falcone M, Besozzi G, [Calcagno A](#), Goletti D, Gualano G, Sotgiu G, Tadolini M, Codecasa L. TB outpatient care in a high-income, low-incidence country. **Int J Tuberc Lung Dis.** 2024 Oct 1;28(10):513-515. doi: 10.5588/ijtld.24.0059. PMID: 39334547.
17. Stroffolini G, Lupia T, Gaviraghi A, Venuti F, Cinnirella G, Gori A, Spotti M, Blasi F, Codecasa L, [Calcagno A](#), Aliberti S; IRENE Study group collaborators. Prescription habits and drugs accessibility for the treatment of non-tuberculous mycobacteria infections in Italy: a multicentric survey from the IRENE study group. **Infection.** 2024 Sep 20. doi: 10.1007/s15010-024-02390-y. Epub ahead of print. PMID: 39302627.
18. Lazzaro A, Vai D, Barco A, Stroffolini G, Pirriatore V, Guastamacchia G, Nigra M, Ghisetti V, Tettoni MC, Noce G, Giaccone C, Trunfio M, Trentalange A, Bonora S, Di Perri G, [Calcagno A](#). Switching to Low Neurotoxic Antiretrovirals to Improve Neurocognition Among People Living With HIV-1-Associated Neurocognitive Disorder: The MARAND-X Randomized Clinical Trial. **J Acquir Immune Defic Syndr.** 2024 Oct 1;97(2):180-191. doi: 10.1097/QAI.0000000000003480. PMID: 39250652.

19. [Calcagno A](#), Cusato J, Cinque P, Marchetti G, Bernasconi D, Trunfio M, Bruzzesi E, Rusconi S, Gabrieli A, Muscatello A, Antinori A, Ripamonti D, Gulminetti R, Antonucci M, Nozza S. Serum and CSF biomarkers in asymptomatic patients during primary HIV infection: a randomized study. **Brain**. 2024 Aug 22;awae271. doi: 10.1093/brain/awae271. Epub ahead of print. PMID: 39171829.
20. Longo BM, Trunfio M, [Calcagno A](#). Dual β -lactams for the treatment of Mycobacterium abscessus: a review of the evidence and a call to act against an antibiotic nightmare. **J Antimicrob Chemother**. 2024 Aug 16;dkae288. doi: 10.1093/jac/dkae288. Epub ahead of print. PMID: 39150384.
21. Trunfio M, Vuaran E, Vai D, Quarta C, Di Stefano A, Imperiale D, Cinnirella G, Bonora S, Di Perri G, Letendre SL, [Calcagno A](#). Symptomatic and Asymptomatic Neurocognitive Impairment, ART Adherence and HIV Control: A 4-Year Observational Study. **AIDS Behav**. 2024 Jul 30. doi: 10.1007/s10461-024-04440-w. Epub ahead of print. PMID: 39080201.
22. Longo BM, Merli M, Achana B, Okao M, Smart Okot G, Ribero S, [Calcagno A](#), Montrucchio G, Orlotti C. A noma case report: A warning message from Northern Uganda. **Trop Med Int Health**. 2024
23. De Vito A, Colpani A, Moi G, Babudieri S, [Calcagno A](#), Calvino V, Ceccarelli M, Colpani G, d'Ettorre G, Di Biagio A, Farinella M, Falaguasta M, Focà E, Giupponi G, Habed AJ, Isenia WJ, Lo Caputo S, Marchetti G, Modesti L, Mussini C, Nunnari G, Rusconi S, Russo D, Saracino A, Serra PA, Madeddu G. Assessing ChatGPT's Potential in HIV Prevention Communication: A Comprehensive Evaluation of Accuracy, Completeness, and Inclusivity. **AIDS Behav**. 2024
24. Trunfio M, Bonora S, di Perri G, [Calcagno A](#). Further considerations on the use of cerebrospinal fluid C-X-C motif chemokine ligand 13 in the diagnosis of neurosyphilis among people with HIV. **AIDS**. 2024
25. Gaviraghi A, de Nicolò A, Venuti F, Stroffolini G, Quaranta M, Cat Genova E, Ponzetta L, Alladio F, Marinaro L, D'Avolio A, [Calcagno A](#). Low azithromycin maximal concentrations in patients concomitantly taking rifampicin: time to move away from rifampicin in the treatment of non-tuberculous mycobacteria? **Antimicrob Agents Chemother**. 2024
26. De Nicolò A, Palermi A, Dispinseri S, Marchetti G, Trunfio M, De Vivo E, D'Avolio A, Muscatello A, Gori A, Rusconi S, Bruzzesi E, Gabrieli A, Bernasconi DP, Bandera A, Nozza S, [Calcagno A](#); INACTION (Italian Network of Acute HIV Infection) study group. Plasma, Intracellular and Lymph Node Antiretroviral Concentrations and HIV DNA Change During Primary HIV Infection: Results from the INACTION P25 Study. **Int J Antimicrob Agents**. 2024
27. Bai F, Bono V, Borghi L, Bonazza F, Falcinella C, Vitaletti V, Miraglia F, Trunfio M, [Calcagno A](#), Cusato J, Vegni E, d'Arminio Monforte A, Marchetti G. Association between tight junction proteins and cognitive performance in untreated persons with HIV. **AIDS**. 2024
28. [Calcagno A](#), Tutone M, Del Re S, Delmonte S, Agosta D, Ghisetti V, Lucchini A. Doxycycline Post-exposure Prophylaxis and Sexually Transmitted Infections in Italy, 2023. **Clin Infect Dis**. 2024
29. Cusato J, Manca A, Palermi A, Mula J, Avataneo V, Antonucci M, Marinaro L, Bonora S, Trunfio M, Di Perri G, D'Avolio A, [Calcagno A](#). Host single nucleotide polymorphisms and biomarkers of neuronal damage and inflammation in people living with HIV. **Int J Antimicrob Agents**. 2024
30. Colpani A, De Vito A, Zauli B, Menzaghi B, [Calcagno A](#), Celesia BM, Ceccarelli M, Nunnari G, De Socio GV, Di Biagio A, Leoni N, Angioni G, Giambenedetto SD, D'Ettorre G, Babudieri S, Madeddu G. Knowledge of Sexually Transmitted Infections and HIV among People Living with HIV: Should We Be Concerned? **Healthcare (Basel)**. 2024
31. Ambrosioni J, Díaz NA, Marzolini C, Dragovic G, Imaz A, [Calcagno A](#), Luque S, Curran A, Troya J, Tuset M, Khoo S, Burger D, Cortés CP, Naous N, Molto J. Outcomes of Drug Interactions Between Antiretrovirals and Co-Medications, Including Over-the-Counter Drugs: A Real-World Study. **Infect Dis Ther**. 2024
32. Aliberti S, Blasi F, Burgel PR, [Calcagno A](#), Fløe A, Grogono D, Papavasileiou A, Polverino E, Prados C, Rohde G, Salzer HJF, Sánchez-Montalvá A, Shteinberg M, Van Braeckel E, van Ingen J, Veziris N, Wagner D, Loebeinger MR. Mycobacterium avium complex pulmonary disease patients with limited treatment options. **ERJ Open Res**. 2024.
33. Ranzani A, Castelli F, Di Biagio A, d'Arminio Monforte A, D'Avolio A, Soria A, Bai F, Focà E, Taramasso L, [Calcagno A](#), Bresciani E, Torsello A, Bonfanti P, Lapadula G. Influence of efavirenz and 8-hydroxy-efavirenz plasma levels on cognition and central nervous system side effects. **HIV Med**. 2023.
34. Tincati C, Bono V, Cannizzo ES, Tosi D, Savi F, Falcinella C, Casabianca A, Orlandi C, Luigiano C, Augello M, Rusconi S, Muscatello A, Bandera A, [Calcagno A](#), Gori A, Nozza S, Marchetti G; on behalf of the Italian Network of ACuTe HIV Infection (INACTION). Primary HIV infection features colonic damage and neutrophil inflammation yet containment of microbial translocation. **AIDS**. 2023.
35. Trunfio M, Sacchi A, Vai D, Pittaluga F, Croce M, Cavallo R, Imperiale D, Bonora S, Di Perri G, Letendre SL, [Calcagno A](#). Intrathecal production of anti-EBV Viral Capsid Antigen IgG is associated with Neurocognition and tau pathology in people with HIV. **AIDS**. 2023.
36. Stroffolini G, Lazzaro A, Barco A, Pirriatore V, Vai D, Giaccone C, Nigra M, Atzori C, Trunfio M, Bonora S, Di Perri G, [Calcagno A](#). Changes in Cerebrospinal Fluid, Liver and Intima-media-thickness Biomarkers in Patients with HIV-associated Neurocognitive Disorders Randomized to a Less Neurotoxic Treatment Regimen. **J Neuroimmune Pharmacol**. 2023.
37. Babiloni C, Del Percio C, Piervincenzi C, Carducci F, Ferri R, Onorati P, Toma G, Ferracuti S, Roma P, Correr V, Di Campli F, Aceti A, Salvatore M, Soricelli A, Teti E, Pennica A, Sarmati L, Vullo V, D'Ettorre G, Mastroianni C, Petsas N, Pantano P, Floris R, Stocchi F, Andreoni M, Di Perri G, [Calcagno A](#), Noce G. Parietal resting-state EEG alpha source connectivity is associated with subcortical white matter lesions in HIV-positive people. **Clin Neurophysiol**. 2023.
38. Global Tuberculosis Network; TB/COVID-19 Global Study Group; TB/COVID-19 Global Study Group; Casco N, Jorge AL, Palmero DJ, Alffenaar JW, Fox GJ, Ezz W, Cho JG, Denholm J, Skrahina A, Solodovnikova V, Arbex MA, Alves T, Rabahi MF, Pereira GR, Sales R, Silva DR, Saffie MM, Salinas NE, Miranda RC, Cisterna C, Concha C, Fernandez I, Villalvén C, Vera CG, Tapia PG, Cancino V, Carbonell M, Cruz A, MuV±oz E, MuV±oz C, Navarro I, Pizarro I, Sv±nchez GPC, Riquelme MSV, Vilca E, Soto A, Flores X, Garavagno A, Bahamondes MH, Merino LM, Pradenas AM, Revillot ME, Rodriguez P, Salinas AS, Taiba C, ValdV©s JF, Subiabre JN, Ortega C, Palma S, Castillo PP, Pinto M, Bidegain FR, Venegas M, Yucra E, Li Y, Cruz A, Guelvez B, Plaza RV, Hoyos KYT, Van Den Boom M, Andrv©jak C, Blanc FX, Dourmane S, Froissart A, Izadifar A, Riviv®re F, Schlemmer F, Manika K, Diallo BD, Hassane-Harouna S, Artilles N, Mejia LA, Gupta N, Ish P, Mishra G, Patel JM, Singla R, Udwadia ZF, Alladio F, Angeli F, [Calcagno A](#), Centis R, Codecasa LR, De Lauretis A, Esposito SMR, Formenti B, Gaviraghi A, Giacomet V, Goletti D, Gualano G, Matteelli A, Migliori GB, Motta I, Palmieri F, Pontali E, Prestileo T, Riccardi N, Saderi L, Sapor,Ä. Long-term outcomes of the global TB and COVID-19 coinfection cohort. **Eur Respir J**. 2023.
39. Longo BM, Venuti F, Gaviraghi A, Lupia T, Ranzani FA, Pepe A, Ponzetta L, Vita D, Alice T, Gregorc V, Frascione PMM, De Rosa FG, [Calcagno A](#), Bonora S. Sequential or Combination Treatments as Rescue Therapies in Immunocompromised Patients with Persistent SARS-CoV-2 Infection in the Omicron Era: A Case Series. **Antibiotics (Basel)**. 2023.

40. Bruzzesi E, Gabrieli A, Bernasconi D, Marchetti G, [Calcagno A](#), Ripamonti D, Antinori A, Squillace N, Cingolani A, Muscatello A, Bandera A, Gori A, Rusconi S, Nozza S; INACTION Study Group. HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial. **J Med Virol.** **2023**.
41. De Benedetto I, Biagini F, Urbano G, Mongini TE, Cassetta I, Scaglione L, Curtioni A, Calleri G, [Calcagno A](#), De Rosa FG, Corcione S. A case of histological diagnosis of Toxoplasma gondii myositis in a person living with HIV. **Infez Med.** **2023**.
42. Venuti F, Gaviraghi A, De Nicolò A, Stroffolini G, Longo BM, Di Vincenzo A, Ranzani FA, Quaranta M, Romano F, Catellani E, Marchiaro C, Cinnirella G, D'Avolio A, Bonora S, [Calcagno A](#). Real-Life Experience of Continuously Infused Ceftolozane/Tazobactam in Patients with Bronchiectasis and Multidrug-Resistant Pseudomonas aeruginosa Infection in the Outpatient Setting. **Antibiotics (Basel).** **2023**.
43. Venuti F, Trunfio M, Martson AG, Lipani F, Audagnotto S, Di Perri G, [Calcagno A](#). Extended and Continuous Infusion of Novel Protected Beta-Lactam Antibiotics: A Narrative Review. **Drugs.** **2023**.
44. Di Girolamo L, Ferrara M, Trevisan G, Longo BM, Alice T, Burdino E, Alladio F, Fantino S, Di Perri G, [Calcagno A](#), Bonora S. Transient plasma viral rebound after SARS-CoV-2 vaccination in an exceptional HIV-1 elite controller woman. **Virol J.** **2023**.
45. De Vito A, Colpani A, Trunfio M, Fiore V, Moi G, Fois M, Leoni N, Rui S, Babudieri S, [Calcagno A](#), Madeddu G. Living with HIV and Getting Vaccinated: A Narrative Review. **Vaccines (Basel).** **2023**.
46. Cusato J, Manca A, Palermi A, Mula J, Costanzo M, Antonucci M, Trunfio M, Corcione S, Chiara F, De Vivo ED, Ianniello A, Ferrara M, Di Perri G, De Rosa FG, D'Avolio A, [Calcagno A](#). COVID-19: A Possible Contribution of the MAPK Pathway. **Biomedicines.** **2023**
47. Cusato J, Manca A, Palermi A, Mula J, Costanzo M, Antonucci M, Chiara F, De Vivo ED, Maiese D, Ferrara M, Bonora S, Di Perri G, D'Avolio A, [Calcagno A](#). COVID-19: Focusing on the Link between Inflammation, Vitamin D, MAPK Pathway and Oxidative Stress Genetics. **Antioxidants (Basel).** **2023**
48. Trunfio M, Mighetto L, Napoli L, Atzori C, Nigra M, Guastamacchia G, Bonora S, Di Perri G, [Calcagno A](#). Cerebrospinal Fluid CXCL13 as Candidate Biomarker of Intrathecal Immune Activation, IgG Synthesis and Neurocognitive Impairment in People with HIV. **J Neuroimmune Pharmacol.** **2023**
49. Ecarnot F, Boccardi V, [Calcagno A](#), Franceschi C, Fülöp T, Itzhaki RF, Michel JP, Panza F, Rainero I, Solfrizzi V, Ticinesi A, Veronese N, Maggi S. Dementia, infections and vaccines: 30 years of controversy. **Aging Clin Exp Res.** **2023**
50. Trunfio M, Pinnetti C, Arsuffi S, Bai F, Celani L, D'Ettorre G, Vera JH, D'Arminio Monforte A, Focà E, Ghisetti V, Bonora S, Antinori A, [Calcagno A](#). The presence of resistance-associated mutations in reverse transcriptase gene is associated with cerebrospinal fluid HIV-1 escape: A multicentric retrospective analysis. **J Med Virol.** **2023**
51. Trunfio M, Pinnetti C, Arsuffi S, Bai F, Celani L, D'Ettorre G, Vera JH, Monforte AD, Focà E, Ghisetti V, Bonora S, Antinori A, [Calcagno A](#). The Presence of Resistance-associated Mutations in Reverse Transcriptase Gene is Associated with Cerebrospinal Fluid HIV-1 Escape: a multicentric retrospective analysis. **J Med Virol.** **2023** Mar 26.
52. Stroffolini G, Gaviraghi A, Penna D, Piccioni P, Venuti F, Botto C, Trezzi M, Betti M, Sestini S, Erba PA, Lupia T, Di Perri G, Aliberti S, [Calcagno A](#). 18-fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with non-tuberculous mycobacterial infections: A case series on the use of Nuclear Medicine in NTM-PD. **J Infect.** **2023** Mar 17:S0163-4453(23)00142-1.
53. Cusato J, Avataneo V, Antonucci M, Trunfio M, Marinaro L, Palermi A, Manca A, Di Perri G, Mula J, Bonora S, D'Avolio A, [Calcagno A](#). Antiretroviral Levels in the Cerebrospinal Fluid: The Effect of Inflammation and Genetic Variants. **Diagnostics (Basel).** **2023**.
54. Cusato J, Borghetti A, Teti E, Milesi M, Tettoni MC, Bonora S, Trunfio M, D'Avolio A, Compagno M, Di Giambenedetto S, Di Perri G, [Calcagno A](#). Dolutegravir Discontinuation for Neuropsychiatric Symptoms in People Living with HIV and Their Outcomes after Treatment Change: A Pharmacogenetic Study. **Metabolites.** **2022**.
55. Manzini PM, Ciccone G, De Rosa FG, Cavallo R, Ghisetti V, D'Antico S, Galassi C, Saccona F, Castiglione A, Birocco N, Francisci T, Hu H, Pecoraro C, Danielle F, Labanca L, Bordiga AM, Lorenzi M, Camisasca G, Giachino O, Pagliarino M, Ottone P, Scuvera ITD, Guaschino R, Freilone R, Berti P, Pittaluga F, Avolio M, Costa C, Raso S, Nucci A, Milan M, Baffa A, Russo A, Tornello A, Maddalena L, Delios G, Marletto FP, De Micheli AG, Mattei A, Baldassano S, Canta F, Russo ML, Bergamo D, Vitale F, Liccardi MM, Chinaglia A, [Calcagno A](#), Converso M, Aldieri C, Libanore V, Blangetti I, Benedetti V, Mitola B, Scozzari G; PLACO COVID Study Group. Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: short and long-term effects. A three-arm randomized controlled clinical trial. **BMC Infect Dis.** **2022**
56. Sciascia S, Arbrile M, Trunfio M, [Calcagno A](#), Radin M, Roccatello D, Lembo D, Civra A. The role of bacteria and viruses in Behçet syndrome: Should we move towards new paradigms? **Autoimmun Rev.** **2022**
57. Trunfio M, Di Girolamo L, Ponzetta L, Russo M, Burdino E, Imperiale D, Atzori C, Di Perri G, [Calcagno A](#). Seropositivity and reactivations of HSV-1, but not of HSV-2 nor VZV, associate with altered blood-brain barrier, beta amyloid, and tau proteins in people living with HIV. **J Neurovirol.** **2022**
58. Riccardi N, Antonello RM, Giacomelli A, Saderi L, Canetti D, Pallotto C, Mazzaferri F, Degli Antoni AM, Cardellino C, Motta I, [Calcagno A](#), Falcone M, Trezzi M, Comelli A, Pascale R, Merli M, Binda F, Angheben A, Sotgiu G, Gobbi F, Nozza S. The challenge of infectious diseases consultations in the emergency department: an Italian nationwide survey. **New Microbiol.** **2022**.
59. De Nicolò A, [Calcagno A](#), Motta I, De Vivo E, D'Avolio A, Di Perri G, Wiesner L, Ebrahim IE, Maertens G, Orrell C, McIlleron H. The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study. **Antimicrob Agents Chemother.** **2022** Jun 21;66(6):e0013622.
60. Cusato J, Palermi A, Manca A, Mula J, Antonucci M, De Nicolò A, Allegra S, De Francia S, Chiara F, Di Perri G, Rosa FG, [Calcagno A](#), D'Avolio A. Antifungal Drug Plasma Exposures: A Possible Contribution of Vitamin D-Related Gene Variants. **Pharmaceuticals (Basel).** **2022** May 20;15(5):630.
61. Ochoa-Azpe R, Chang-Monteagudo A, Climent-Ruiz Y, Macías-Abraham C, Valenzuela-Silva C, de Los Angeles García-García M, Jerez-Barceló Y, Triana- Marrero Y, Ruiz-Villegas L, Dairon Rodríguez-Prieto L, Guerra-Chaviano PP, Sánchez-Ramírez B, Hernández-García T, Orosa-Vázquez I, Díaz-Hernández M, Chiodo F, [Calcagno A](#), Ghisetti V, Rodríguez-Acosta M, Noa-Romero E, Enríquez-Puertas J, Ortega-León D, Valdivia-Álvarez I, Delahanty-Fernández A, Palenzuela-Díaz A, Rodríguez-Noda L, González-Mugica R, Valdés-Balbín Y, García-Rivera D, Verez-Bencomo V. Safety and immunogenicity of

- the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial. **Lancet Respir Med.** **2022** Aug;10(8):785-795.
62. De Benedetto I, Barco A, Rossi M, Lapadula G, Lupia T, Bonfanti P, Bonora S, Di Perri G, [Calcagno A](#). BCGitis after Bacille Calmette-Guerin intravesical administration from two referral centers: clinical characteristics and risk factors. **Infez Med.** **2022** Jun 1;30(2):242-246.
 63. Trunfio M, Scabini S, Rugge W, Bonora S, Di Perri G, [Calcagno A](#). Concurrent and Subsequent Co-Infections of *Clostridioides difficile* Colitis in the Era of Gut Microbiota and Expanding Treatment Options. **Microorganisms.** **2022** Jun 23;10(7):1275.
 64. Mastorino L, Dapavo P, Trunfio M, Avallone G, Rubatto M, [Calcagno A](#), Ribero S, Quaglini P. Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy. **Acta Derm Venereol.** **2022** Sep 6. doi: 10.2340/actadv.v102.1982.
 65. Trunfio M, Portesani F, Vicinanza S, Nespoli P, Traverso F, Cortese G, Bonora S, [Calcagno A](#), Di Perri G. Real-life Evidence of Lower Lung Virulence in COVID-19 Inpatients Infected with SARS-CoV-2 Omicron Variant Compared to Wild-type and Delta SARS-CoV-2 Pneumonia. **Lung.** **2022** Oct;200(5):573-577.
 66. Ferrara M, Cusato J, Salvador E, Trentalange A, Alcantarini C, Trunfio M, Cannizzo ES, Bono V, Nozza S, De Nicolò A, Ianniello A, De Vivo E, D'Avolio A, Di Perri G, Bonora S, Marchetti G, [Calcagno A](#). Inflammation and Intracellular Exposure of Dolutegravir, Darunavir, Tenofovir and Emtricitabine in People living with HIV. **Br J Clin Pharmacol.** **2022** Sep 17.
 67. Trunfio M, Atzori C, Pasquero M, Di Stefano A, Vai D, Nigra M, Imperiale D, Bonora S, Di Perri G, [Calcagno A](#). Patterns of Cerebrospinal Fluid Alzheimer's Dementia Biomarkers in People Living with HIV: Cross-Sectional Study on Associated Factors According to Viral Control, Neurological Confounders and Neurocognition. **Viruses.** **2022** Apr 4;14(4):753.
 68. Trunfio M, Richiardi L, Alladio F, Staffilano E, Longo B, Venuti F, Ghisetti V, Burdino E, Bonora S, Vineis P, Di Perri G, [Calcagno A](#). Determinants of SARS-CoV-2 Contagiousness in Household Contacts of Symptomatic Adult Index Cases. **Front Microbiol.** **2022** Apr 1;13:829393.
 69. Stroffolini G, Rossi L, Lupia T, Faraoni S, Paltrinieri G, Lipani F, [Calcagno A](#), Bonora S, Di Perri G, Calleri G. Trichinella britovi outbreak in Piedmont, North-West Italy, 2019-2020: Clinical and epidemiological insights in the one health perspective. **Travel Med Infect Dis.** **2022**.
 70. Avataneo V, Palermiti A, De Nicolò A, Cusato J, Giussani G, [Calcagno A](#), D'Avolio A. Monthly Increase in Vitamin D Levels upon Supplementation with 2000 IU/Day in Healthy Volunteers: Result from "Integriamoci", a Pilot Pharmacokinetic Study. **Molecules.** **2022**. Feb 3;27(3):1042. Impact Factor 4.412.
 71. Babiloni C, Del Percio C, Lizio R, Lopez S, Pennica A, Roma P, Correr V, Cucciolla F, Toma G, Soricelli A, Di Campi F, Aceti A, Teti E, Sarmati L, Crocetti G, Ferri R, Lorenzo I, Galli M, Negri C, Angarano G, Saracino A, Lepore L, Di Pietro M, Fusco FM, Vullo V, D'Ettorre G, Pagliano P, Di Flumeri G, Celesia BM, Gentilini Cacciola E, Di Perri G, [Calcagno A](#), Stocchi F, Ferracuti S, Onorati P, Andreoni M, Noce G. Parietal intrahemispheric source connectivity of resting-state electroencephalographic alpha rhythms is abnormal in Naïve HIV patients. **Brain Res Bull.** **2022**. Apr;181:129-143. Impact factor 4.079.
 72. Barco A, Orlando S, Stroffolini G, Pirriatore V, Lazzaro A, Vai D, Guastamacchia G, Noce G, Atzori C, Trunfio M, Bonora S, Di Perri G, [Calcagno A](#). Correlations between cerebrospinal fluid biomarkers, neurocognitive tests, and resting-state electroencephalography (rsEEG) in patients with HIV-associated neurocognitive disorders. **J Neurovirol.** **2022**. Impact Factor 2.643.
 73. Trunfio M, De Francesco D, Vai D, Medina C, Milesi M, Domini S, Alcantarini C, Imperiale D, Bonora S, Di Perri G, [Calcagno A](#). Screening Accuracy of Mini Addenbrooke's Cognitive Examination Test for HIV-Associated Neurocognitive Disorders in People Ageing with HIV. **AIDS Behav.** **2022**. Impact Factor 3.895.
 74. Trunfio M, Verga F, Ghisetti V, Burdino E, Emanuele T, Bonora S, Di Perri G, [Calcagno A](#). Clinical Phenotype and Contagiousness of Early Breakthrough SARS-CoV-2 Infections after BNT162b2 COVID-19 mRNA Vaccine: A Parallel Cohort Study in Healthcare Workers. **Vaccines (Basel).** **2021**. Impact factor 4.422.
 75. Stroffolini G, Segala FV, Lupia T, Faraoni S, Rossi L, Tomassone L, Zanet S, De Rosa FG, Di Perri G, [Calcagno A](#). Serology for Borrelia spp. in Northwest Italy: A Climate-Matched 10-Year Trend. **Life (Basel).** **2021**. Impact Factor 3.817.
 76. [Calcagno A](#), Celani L, Trunfio M, Orofino G, Imperiale D, Atzori C, Arena V, d'Ettorre G, Guaraldi G, Gisslen M, Di Perri G. Alzheimer Dementia in People Living With HIV. **Neurol Clin Pract.** **2021**. Impact Factor 1.241.
 77. Stroffolini G, Guastamacchia G, Audagnotto S, Atzori C, Trunfio M, Nigra M, Di Stefano A, Di Perri G, [Calcagno A](#). Low cerebrospinal fluid Amyloid-Beta 1-42 in patients with tuberculous meningitis. **BMC Neurol.** **2021**. Impact Factor 2.293.
 78. TB/COVID-19 Global Study Group. Tuberculosis and COVID-19 co-infection: description of the global cohort. **Eur Respir J.** **2021** [Epub ahead of print] Impact factor 16.670.
 79. Ulfhammer G, Edén A, Antinori A, Brew BJ, [Calcagno A](#), Cinque P, De Zan V, Hagberg L, Lin A, Nilsson S, Oprea C, Pinnetti C, Spudich S, Trunfio M, Winston A, Price RW, Gisslén M. Cerebrospinal Fluid viral load across the spectrum of untreated HIV-1 infection: a cross-sectional multi-center study. **Clin Infect Dis.** **2021** [Epub ahead of print] Impact factor 8.313.
 80. Airoldi C, [Calcagno A](#), Di Perri G, Valinotto R, Gallo L, Locana E, Trunfio M, Patrucco F, Vineis P, Faggiano F. Seroprevalence of SARS-CoV-2 Among Workers in Northern Italy. **Ann Work Expo Health.** **2021**. Impact factor 1.81
 81. Trunfio M, Scabini S, Mornese Pinna S, Rugge W, Alcantarini C, Pirriatore V, Di Perri G, Bonora S, Castelnovo B, [Calcagno A](#). The Manifesto of Pharmacoenosis: Merging HIV Pharmacology into Pathocoenosis and Syndemics in Developing Countries. **Microorganisms.** **2021** Jul 31;9(8):1648. Impact factor 4.128.
 82. Cusato J, Mula J, Palermiti A, Manca A, Antonucci M, Avataneo V, De Vivo ED, Ianniello A, [Calcagno A](#), Di Perri G, De Nicolò A, D'Avolio A. Seasonal Variation of Antiretroviral Drug Exposure during the Year: The Experience of 10 Years of Therapeutic Drug Monitoring. **Biomedicines.** **2021** Sep 12;9(9):1202.
 83. Parietti M, Trunfio M, Delmonte S, Conti L, Trentalange A, Bonora S, [Calcagno A](#), Ribero S. Efflorescence of acquired epidermodysplasia verruciformis due to immune reconstitution inflammatory syndrome-like mechanisms following anti-HPV vaccination in a HIV-positive patient. **Int J STD AIDS.** **2021** Oct 11:9564624211048343.
 84. Avallone G, Trunfio M, Mastorino L, Agostini A, Merli M, Rubatto M, Caracciolo D, [Calcagno A](#), Senetta R, Fierro MT, Quaglini P, Ribero S. Case Report: Atypical Cutaneous Presentation of Human T-cell Lymphotropic Virus Type 1-Related Adult T-cell Lymphoma. **Am J Trop Med Hyg.** **2021** Oct 11:tpmd210630.
 85. Focà E, [Calcagno A](#), Calza S, Renzetti S, Chiesa A, Siano M, De Socio G, Piconi S, Orofino G, Madeddu G, Cattelan AM, Nozza S, Ferrara M, Milic J, Celesia BM, Castelli F, Guaraldi G. Durability of Integrase STRand Inhibitor (INSTI)-based regimen in geriatric people living with HIV in the GEPPPO cohort. **PLoS One.** **2021** Oct 13;16(10):e0258533.

86. Cusato J, Tempestilli M, [Calcagno A](#), Vergori A, Piselli P, Antonucci M, Avataneo V, Palermi A, Notari S, Antinori A, Di Perri G, Agrati C, D'Avolio A. Vitamin D as Modulator of Drug Concentrations: A Study on Two Italian Cohorts of People Living with HIV Administered with Efavirenz. **Nutrients**. 2021 Oct 12;13(10):3571.
87. Clerico M, Dogliotti I, [Calcagno A](#), Grimaldi D, Leone S, Ragaini S, Boffini M, Caracciolo D, Ferrero S, Barbero C, Zanotto E, Stroffolini G, Cavallo R, Rinaldi M, Bruno B, Cavallo F. COVID-19 in a Post-transplant Heart Recipient Who Developed Aggressive Lymphoma: A Biphasic Course During Rituximab Treatment. **Hemasphere** 2021.
88. Chan TY, De Zan V, Gregg A, Alagaratnam J, Gerevini S, Antinori A, Monforte AD, Saracino A, Trunfio M, Everitt A, Rackstraw S, Marta M, [Calcagno A](#), Cinque P, Winston A. Cerebrospinal fluid HIV RNA escape symptomatology. **AIDS** 2021.
89. De Nicolò A, Manca A, Ianniello A, Palermi A, [Calcagno A](#), Ferrara M, Antonucci M, Cusato J, Avataneo V, De Vivo E, Bonora S, De Rosa FG, Di Perri G, D'Avolio A. Development and Validation of an Up-to-Date Highly Sensitive UHPLC-MS/MS Method for the Simultaneous Quantification of Current Anti-HIV Nucleoside Analogues in Human Plasma. **Pharmaceuticals (Basel)** 2021.
90. De Nicolò A, Avataneo V, Cusato J, Palermi A, Mula J, De Vivo E, Antonucci M, Bonora S, [Calcagno A](#), Di Perri G, De Rosa FG, D'Avolio A. Analytical Validation and Clinical Application of Rapid Serological Tests for SARS-CoV-2 Suitable for Large-Scale Screening. **Diagnostics (Basel)** 2021.
91. Caligaris G, Trunfio M, Ghisetti V, Cusato J, Nigra M, Atzori C, Imperiale D, Bonora S, Di Perri G, [Calcagno A](#). Blood-Brain Barrier Impairment in Patients Living with HIV: Predictors and Associated Biomarkers. **Diagnostics (Basel)**. 2021.
92. [Calcagno A](#), Trunfio M, D'Avolio A, Di Perri G, Bonora S. The impact of age on antiretroviral drug pharmacokinetics in the treatment of adults living with HIV. **Expert Opin Drug Metab Toxicol** 2021.
93. [Calcagno A](#), de Nicolò A, Pizzi C, Trunfio M, Tettoni C, Ferrara M, Alcantarini C, Trentini L, D'Avolio A, Di Perri G, Bonora S. Medication burden and clustering in people living with HIV undergoing therapeutic drug monitoring. **Br J Clin Pharmacol** 2021.
94. Trunfio M, [Calcagno A](#), Bonora S, Di Perri G. Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases. **Lancet Infect Dis** 2021.
95. Trunfio M, Longo BM, Alladio F, Venuti F, Cerutti F, Ghisetti V, Bonora S, Di Perri G, [Calcagno A](#). On the SARS-CoV-2 "Variation Hypothesis": No Association Between Viral Load of Index Cases and COVID-19 Severity of Secondary Cases. **Front Microbiol** 2021.
96. Ancona G, Merlini E, Tincati C, Barassi A, [Calcagno A](#), Augello M, Bono V, Bai F, Cannizzo ES, d'Arminio Monforte A, Marchetti G. Long-Term Suppressive cART Is Not Sufficient to Restore Intestinal Permeability and Gut Microbiota Compositional Changes. **Front Immunol** 2021.
97. Trunfio M, Venuti F, Alladio F, Longo BM, Burdino E, Cerutti F, Ghisetti V, Bertucci R, Picco C, Bonora S, Di Perri G, [Calcagno A](#). Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic Patients. **Viruses** 2021.
98. Guaraldi G, Calza S, Milic J, [Calcagno A](#), Focà E, Rota M, Renzetti S, Celotti A, Siano M, Celesia BM, Piconi S, de Socio GV, Cattelan AM, Orofino G, Riva A, Nozza S, di Perri G. Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV. **AIDS** 2021.
99. Lin SP, [Calcagno A](#), Letendre SL, Ma Q. Clinical Treatment Options and Randomized Clinical Trials for Neurocognitive Complications of HIV Infection: Combination Antiretroviral Therapy, Central Nervous System Penetration Effectiveness, and Adjuvants. **Curr Top Behav Neurosci** 2021.
100. Trentalange A, Borgogno E, Motta I, Antonucci M, Pirriatore V, Costa C, Rossi G, Barco A, De Nicolò A, Piccioni P, D'Avolio A, Bonora S, Perri GD, [Calcagno A](#). Rifampicin and Isoniazid Maximal Concentrations are Below Efficacy-associated Thresholds in the Majority of Patients: Time to Increase the Doses? **Int J Antimicrob Agents** 2021.
101. The TB/COVID-19 Global Study Group. TB and COVID-19 co-infection: rationale and aims of a global study. **Int J Tuberc Lung Dis** 2021.
102. Trunfio M, Salvador E, Gaviraghi A, Audagnotto S, Marinaro L, Motta I, Casciaro R, Ghisetti V, Fava C, Bonora S, Di Perri G, [Calcagno A](#); e-COVID Study Group. Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity. **Antivir Ther** 2021.
103. De Nicolò A, Ianniello A, Ferrara M, Avataneo V, Cusato J, Antonucci M, De Vivo E, Waitt C, [Calcagno A](#), Trentalange A, Muccioli G, Bonora S, Di Perri G, D'Avolio A. Validation of a UHPLC-MS/MS Method to Quantify Twelve Antiretroviral Drugs within Peripheral Blood Mononuclear Cells from People Living with HIV. **Pharmaceuticals (Basel)** 2020.
104. [Calcagno A](#), Dal Conte I, Cattaneo D, Testi R, Mistrangelo M, Gervasoni C, de Nicolò A, Bonora S, D'Avolio A, Di Perri G. Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders. **Antimicrob Agents Chemother** 2020.
105. Maggiolo F, Bandera A, Bonora S, Borderi M, [Calcagno A](#), Cattelan A, Cingolani A, Gianotti N, Lichtner M, Lo Caputo S, Madeddu G, Maggi P, Marchetti GC, Maserati R, Nozza S, Rusconi S, Zazzi M, Di Biagio A. Enhancing care for people living with HIV: current and future monitoring approaches. **Expert Rev Anti Infect Ther** 2020.
106. Trunfio M, Salvador E, Cabodi D, Marinaro L, Alcantarini C, Gaviraghi A, Trentalange A, Lipani F, Sciascia S, Roccatello D, Bonora S, Di Perri G, [Calcagno A](#); e-COVID Study group. Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection. **Thromb Res** 2020.
107. [Calcagno A](#), Ghisetti V, Emanuele T, Trunfio M, Faraoni S, Boglione L, Burdino E, Audagnotto S, Lipani F, Nigra M, D'Avolio A, Bonora S, Di Perri G. Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, Italy. **Emerg Infect Dis** 2020.
108. [Calcagno A](#), Ghisetti V, Burdino E, Trunfio M, Allice T, Boglione L, Bonora S, Di Perri G. Coinfection with other respiratory pathogens in COVID-19 patients. **Clin Microbiol Infect** 2020.
109. De Benedetto I, Trunfio M, Guastamacchia G, Bonora S, [Calcagno A](#). A review of the potential mechanisms of neuronal toxicity associated with antiretroviral drugs. **J Neurovirol** 2020.
110. [Calcagno A](#), Moltò J, Borghetti A, Gervasoni C, Milesi M, Valle M, Avataneo V, Alcantarini C, Pla-Junca F, Trunfio M, D'Avolio A, Di Giambenedetto S, Cattaneo D, Di Perri G, Bonora S. Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV. **Clin Pharmacokinet** 2020.
111. Trunfio M, Rugge W, Mighetto L, Vai D, Atzori C, Nigra M, Domini S, Borgogno E, Guastamacchia G, Bonora S, Di Perri G, [Calcagno A](#). Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV. **AIDS**. 2020.

112. Taramasso L, Fabbiani M, Nozza S, De Benedetto I, Bruzzesi E, Mastrangelo A, Pinnetti C, [Calcagno A](#), Ferrara M, Bozzi G, Focà E, Quiros-Roldan E, Ripamonti D, Campus M, Celesia BM, Torti C, Cosco L, Di Biagio A, Rusconi S, Marchetti G, Mussini C, Gulminetti R, Cingolani A, d'Ettorre G, Madeddu G, Franco A, Orofino G, Squillace N, Muscatello A, Gori A, Antinori A, Tambussi G, Bandera A; INACTION study group. Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV InfectiON (INACTION) cohort. **HIV Med** 2020.
113. Dravid AN, Gawali R, Betha TP, Sharma AK, Medisetty M, Natrajan K, Kulkarni MM, Saraf CK, Mahajan US, Kore SD, Rathod NM, Mahajan US, Letendre SL, Wadia RS, [Calcagno A](#). Two treatment strategies for management of Neurosymptomatic cerebrospinal fluid HIV escape in Pune, India. **Medicine (Baltimore)** 2020.
114. Sciascia S, Aprà F, Baffa A, Baldovino S, Boaro D, Boero R, Bonora S, [Calcagno A](#), Cecchi I, Cinnirella G, Converso M, Cozzi M, Crosasso P, De Iaco F, Di Perri G, Eandi M, Fenoglio R, Giusti M, Imperiale D, Imperiale G, Livigni S, Manno E, Massara C, Milone V, Natale G, Navarra M, Oddone V, Osella S, Piccioni P, Radin M, Roccatello D, Rossi D. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. **Clin Exp Rheumatol** 2020.
115. Muscatello A, Nozza S, Fabbiani M, De Benedetto I, Ripa M, Dell'acqua R, Antinori A, Pinnetti C, [Calcagno A](#), Ferrara M, Focà E, Quiros-Roldan E, Ripamonti D, Campus M, Maurizio Celesia B, Torti C, Cosco L, Di Biagio A, Rusconi S, Marchetti G, Mussini C, Gulminetti R, Cingolani A, D'ettorre G, Madeddu G, Franco A, Orofino G, Squillace N, Gori A, Tambussi G, Bandera A; Inaction Study Group. Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection-Results of Italian Network of ACuTe HIV InfectiON (INACTION) Retrospective Study. **Pathog Immun** 2020.
116. Mornese Pinna S, Trunfio M, Imperiale D, [Calcagno A](#). JC virus DNA in cerebrospinal fluid: insight into clinical significance. **Diagn Microbiol Infect Dis** 2020.
117. Lupia T, Milia MG, Atzori C, Gianella S, Audagnotto S, Imperiale D, Mighetto L, Pirriatore V, Gregori G, Lipani F, Ghisetti V, Bonora S, Di Perri G, [Calcagno A](#). Presence of Epstein-Barr virus DNA in cerebrospinal fluid is associated with greater HIV RNA and inflammation. **AIDS** 2020.
118. Joseph SB, Trunfio M, Kincer LP, [Calcagno A](#), Price RW. What can characterization of cerebrospinal fluid escape populations teach us about viral reservoirs in the central nervous system? **AIDS** 2019.
119. Lwanga I, Nabaggala MS, Kiragga A, [Calcagno A](#), Guaraldi G, Lamorde M, Castelnuovo B. Implementing routine physical function screening among elderly HIV-positive patients in Uganda. **AIDS Care** 2019.
120. Goletti D, Navarra A, Petruccioli E, Cimaglia C, Compagno M, Cuzzi G, De Carli G, Fondaco L, Franzetti F, Giannetti A, Gori A, Lapadula G, Lichtner M, Mastroianni CM, Mazzotta V, Orchi N, Pavone P, Piacentini D, Pirriatore V, Pontali E, Sarmati L, Spolti A, Tacconelli E, Galli M, Antinori A, [Calcagno A](#), Girardi E. Latent tuberculosis infection screening in persons newly-diagnosed with HIV infection in Italy: A multicentre study promoted by the Italian Society of Infectious and Tropical Diseases. **Int J Infect Dis**. 2020.
121. Lupia T, Scabini S, Stroffolini G, [Calcagno A](#). I have got you under my skin. **Infection** 2020.
122. Montrucchio C, De Nicolò A, D'Ettorre G, D'Ascenzo F, Lazzaro A, Tettoni M, D'Avolio A, Bonora S, Celani L, Di Perri G, [Calcagno A](#). Serum Trimethylamine-N-oxide Concentrations in People Living with HIV and the Effect of Probiotic Supplementation. **Int J Antimicrob Agents**. 2020.
123. Costa C, Scabini S, Kaimal A, Kasozi W, Cusato J, Kafufu B, Borderi M, Mwaka E, Di Perri G, Lamorde M, [Calcagno A](#), Castelnuovo B. Calcaneal quantitative ultrasound and urine retinol binding protein in HIV-positive antiretroviral-treated patients in Uganda: a pilot study. **J Infect Dis** 2020.
124. [Calcagno A](#), Cusato J, Ferrara M, De Nicolò A, Lazzaro A, Manca A, D'Avolio A, Di Perri G, Bonora S. Antiretroviral concentrations in the presence and absence of valproic acid. **J Antimicrob Chemother** 2020.
125. Cusato J, [Calcagno A](#), Marinaro L, Avataneo V, D'Avolio A, Di Perri G, Bonora S. Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients. **Pharmacogenomics J** 2019.
126. Focà E, Magro P, Guaraldi G, Riva A, Cattelan AM, De Socio GV, Costa C, Piconi S, Celesia BM, Nozza S, Orofino G, Castagna A, Di Perri G, Castelli F, [Calcagno A](#); GEPPPO (GEriatric Patients living with HIV/AIDS: a Prospective Multidimensional cOhort) Study Group. Elderly HIV-positive women: A gender-based analysis from the Multicenter Italian "GEPPPO" Cohort. **PLoS One** 2019.
127. Trunfio M, Manini C, Trentalange A, Boghi A, Audagnotto S, Imperiale D, Taraglio S, Bonora S, Di Perri G, [Calcagno A](#). The "milky way" galaxy of HIV-related central nervous system immune reaction syndromes. **J Neurovirol** 2019.
128. Di Stefano A, Alcantarini C, Atzori C, Lipani F, Imperiale D, Burdino E, Audagnotto S, Mighetto L, Milia MG, Di Perri G, [Calcagno A](#). Cerebrospinal fluid biomarkers in patients with central nervous system infections: a retrospective study. **CNS Spectr** 2019.
129. Armenia D, Di Carlo D, Cozzi-Lepri A, [Calcagno A](#), Borghi V, Gori C, Bertoli A, Gennari W, Bellagamba R, Castagna A, Latini A, Pinnetti C, Cicalini S, Saracino A, Lapadula G, Rusconi S, Castelli F, Di Giambenedetto S, Andreoni M, Di Perri G, Antinori A, Mussini C, Ceccherini-Silberstein F, Monforte AD, Perno CF, Santoro MM; ICONA Foundation Study Group. Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen. **Antivir Ther** 2019.
130. Cusato J, [Calcagno A](#), De Nicolò A, Mogyrosi K, D'Avolio A, Di Perri G, Bonora S. Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate are not transported by Concentrative Nucleoside Transporter 2. **Diagn Microbiol Infect Dis** 2019.
131. Sekaggya-Wiltshire C, Chirehwa M, Musaazi J, von Braun A, Buzibye A, Muller D, Gutteck U, Motta I, [Calcagno A](#), Fehr JS, Kambugu A, Castelnuovo B, Lamorde M, Denti P. Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines? **Antimicrob Agents Chemother** 2019.
132. Ssebambulidde K, Segawa I, Laker E, Lamorde M, Castelnuovo B, Nakasujja N, [Calcagno A](#). Symptomatic cerebrospinal fluid HIV-1 escape in two patients on second-line antiretroviral therapy in Uganda. **Oxf Med Case Reports**. 2019. *Not Impacted*.
133. [Calcagno A](#), Cusato J, Sekaggya-Wiltshire C, von Braun A, Motta I, Turyasingura G, Castelnuovo B, Fehr J, Di Perri G, Lamorde M. The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Co-infected Patients in Uganda in the SOUTH Study. **Clin Pharmacol Ther** 2019.

134. Pinzone MR, Ceccarelli M, Venanzi Rullo E, Maresca M, Bruno R, Condorelli F, Di Rosa M, Madeddu G, Focà E, [Calcagno A](#), Celesia BM, Cacopardo B, Nunnari G, Pellicanò GF. Circulating angiopoietin-like protein 2 levels are associated with decreased renal function in HIV+ subjects on cART: A potential marker of kidney disease. **Biomed Rep. 2019. Not Impacted.**
135. Peyracchia M, Verardi R, Rubin SR, Abu-Assi E, Montrucchio C, Perl L, Grossomarra W, [Calcagno A](#), Omedè P, Montefusco A, Bonora S, Moretti C, D'Amico M, Mauro R, D'Ascenzo F. In-hospital and long-term outcomes of HIV-positive patients undergoing PCI according to kind of stent: a meta-analysis. **J Cardiovasc Med (Hagerstown) 2019.**
136. Mondì A, Cozzi-Lepri A, Tavelli A, Rusconi S, Vichi F, Ceccherini-Silberstein F, [Calcagno A](#), De Luca A, Maggiolo F, Marchetti G, Antinori A, d'Arminio Monforte A; Ico Foundation Study Group. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Ico cohort. **J Int AIDS Soc 2019.**
137. Lupia T, Costa C, Forni N, [Calcagno A](#). A "Tinea" immune reconstitution inflammatory syndrome in a HIV-positive patient starting combination antiretroviral treatment. **G Ital Dermatol Venereol 2019.**
138. Bertero L, Joseph SB, Trunfio M, Allice T, Catera S, Imperiale D, Cassoni P, Kincer LP, Pirriatore V, Ghisetti V, Amasio E, Zanusso G, Bonora S, Di Perri G, [Calcagno A](#). HIV-1 detection in the olfactory mucosa of HIV-1 infected participants. **AIDS 2019.**
139. Borghetti A, Calcagno A, Lombardi F, Cusato J, Belmonti S, D'Avolio A, Ciccarelli N, La Monica S, Colafigli M, Delle Donne V, De Marco R, Tamburrini E, Visconti E, Di Perri G, De Luca A, Bonora S, Di Giambenedetto S. SLc22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV. **J Antimicrob Chemother 2018.**
140. Trunfio M, Pinnetti C, Focà E, Bai F, Maffongelli G, Celani L, Cinque P, Celotti A, Andreoni M, Monforte AD, D'Ettorre G, Antinori A, [Calcagno A](#). Cerebrospinal fluid HIV-1 escape according to different thresholds and underlying comorbidities: is it time to assess the definitions? **AIDS 2018.**
141. Di Perri G, [Calcagno A](#), Trentalange A, Bonora S. The clinical pharmacology of integrase inhibitors. **Expert Rev Clin Pharmacol 2018.**
142. [Calcagno A](#), Fiumanò M, Zugna D, Cusato J, Montrucchio C, Marinaro L, Trentini L, Ferrara M, D'Avolio A, Pizzi C, Di Perri G, Bonora S. Tenofovir disoproxil fumarate discontinuation for renal outcomes: any room for treatment personalization? **Pharmacogenomics J 2019.**
143. von Braun A, Castelnuovo B, Ledergerber B, Cusato J, Buzibye A, Kambugu A, Fehr J, [Calcagno A](#), Lamorde M, Sekaggya-Wiltshire C. High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment. **J Antimicrob Chemother 2019.**
144. Trentalange A, Prochet A, Imperiale D, Cusato J, Tettoni M, Nunnari G, Barco A, Bonora S, Di Perri G, [Calcagno A](#). Cerebral white matter Hyperintensities in HIV-positive patients. **Brain Imaging Behav 2018.**
145. Aliberti S, Codecasa LR, Gori A, Sotgiu G, Spotti M, Di Biagio A, [Calcagno A](#), Nardini S, Assael BM, Tortoli E, Besozzi G, Ferrarese M, Matteelli A, Girardi E, De Lorenzo S, Seia M, Gramegna A, Del Prato B, Terranova L, Oriano M, Sverzellati N, Mirsaeidi M, Chalmers JD, Haworth CS, Loebinger MR, Aksamit T, Winthrop K, Ringshausen FC, Prevedi G, Blasi F; IRENE Network. The Italian registry of pulmonary non-tuberculous mycobacteria - IRENE: the study protocol. **Multidiscip Respir Med 2018. Not Impacted.**
146. Merlini E, Iannuzzi F, [Calcagno A](#), Bai F, Trunfio M, d'Arminio Monforte A, Bonora S, Marchetti G. Peripheral and cerebrospinal fluid immune activation and inflammation in chronically HIV-infected patients before and after virally suppressive combination antiretroviral therapy (cART). **J Neurovirol 2018.**
147. Scabini S, Trunfio M, Pirriatore V, Imperiale D, Audagnotto S, Bertucci R, Ghisetti V, Cinnirella G, Cistaro A, Perna M, [Calcagno A](#), Di Perri G. Antiviral activity of maraviroc plus mirtazapine in a low-risk HIV-negative patient with progressive multifocal leukoencephalopathy. **Infez Med 2018. Not Impacted.**
148. Allegra S, Cardellino CS, Fatiguso G, Cusato J, De Nicolò A, Avataneo V, Bonora S, D'Avolio A, Di Perri G, [Calcagno A](#). Effect of ABCG2 and ABCG2 Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations. **J Clin Pharmacol 2018.**
149. Focà E, Cavaglià G, Rusconi S, Cascavilla A, Cenderello G, Re A, Casari S, van den Bogaart L, Zinzani PL, Caracciolo D, Di Perri G, Bonito A, Lucchini A, Cassola G, Viale P, [Calcagno A](#). Survival in HIV-infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study. **HIV Med 2018.**
150. Peyracchia M, De Lio G, Montrucchio C, Omedè P, d'Ettore G, [Calcagno A](#), Vullo V, Cerrato E, Pennacchi M, Sardella G, Manga P, Grossomarra W, Vullo F, Fedele F, Biondi-Zoccai G, Moretti C, Vachiat A, Bonora S, Rinaldi M, Mancone M, D'Ascenzo F. Evaluation of coronary features of HIV patients presenting with ACS: The CUORE, a multicenter study. **Atherosclerosis 2018.**
151. Trunfio M, Vai D, Montrucchio C, Alcantarini C, Livelli A, Tettoni MC, Orofino G, Audagnotto S, Imperiale D, Bonora S, Di Perri G, [Calcagno A](#). Diagnostic accuracy of new and old cognitive screening tools for HIV-associated neurocognitive disorders. **HIV Med 2018.**
152. Focà E, [Calcagno A](#), Bonito A, Cusato J, Domenighini E, D'Avolio A, Quiros Roldan E, Trentini L, Castelnuovo F, Di Perri G, Castelli F, Bonora S. Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir. **Antimicrob Agents Chemother 2018.**
153. Guaraldi G, Malagoli A, [Calcagno A](#), Mussi C, Celesia BM, Carli F, Piconi S, De Socio GV, Cattelan AM, Orofino G, Riva A, Focà E, Nozza S, Di Perri G. The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65 - 74 years and more than 75 years. **BMC Geriatr 2018.**
154. [Calcagno A](#), Pinnetti C, De Nicolò A, Scarvaglieri E, Gisslen M, D'Avolio A, Fedele V, Di Perri G, Antinori A, Bonora S. Cerebrospinal fluid abacavir concentrations in HIV-positive patients following once-daily administration. **Br J Clin Pharmacol. 2018.**
155. Bigliano P, [Calcagno A](#), Lucchini A, Audagnotto S, Montrucchio C, Marinaro L, Alcantarini C, Ghisetti V, Di Perri G, Bonora S. The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment. **Antivir Ther 2018.**
156. [Calcagno A](#), Barco A, Trunfio M, Bonora S. CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose. **Curr HIV/AIDS Rep 2018.**
157. Palazzo A, Trunfio M, Pirriatore V, Milesi M, De Nicolò A, Alcantarini C, D'Avolio A, Bonora S, Di Perri G, [Calcagno A](#). Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid. **J Antimicrob Chemother 2017.**

158. Trunfio M, Joseph SB, Ghisetti V, Romito A, Martini C, Cusato J, Audagnotto S, Pesci Kincer L, Ferrara M, Sala A, Imperiale D, Di Perri G, [Calcagno A](#). Symptomatic cerebrospinal fluid HIV-1 escape with no resistance-associated mutations following low-level plasma viremia. **J Neurovirol**. 2017.
159. Motta I, [Calcagno A](#), Bonora S. Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization? **Expert Opin Drug Metab Toxicol** 2018.
160. Cusato J, Allegra S, Nicolò A, [Calcagno A](#), D'Avolio A. Precision medicine for HIV: where are we? **Pharmacogenomics**. 2018.
161. Motta I, Trunfio M, [Calcagno A](#), Pirriatore V, Scabini S, Palazzo A, Audagnotto S, Fatiguso G, Liberini V, Bellò M, D'Avolio A, Di Perri G, Bonora S. Undetectable antimicrobial plasma concentrations in an HIV-positive patient with protein-losing enteropathy and chylothorax during *Mycobacterium genavense* and Leishmania abdominal infections. **J Antimicrob Chemother** 2017.
162. Focà E, [Calcagno A](#), Bonito A, Simiele M, Domenighini E, D'Avolio A, Quiros Roldan E, Trentini L, Casari S, Di Perri G, Castelli F, Bonora S. Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients. **J Antimicrob Chemother** 2017.
163. [Calcagno A](#), Piconi S, Focà E, Nozza S, Carli F, Montrucchio C, Cattelan AM, Orofino G, Celesia BM, Morena V, De Socio GV, Guaraldi G; GEPO (GERiatric Patients living with HIV/AIDS: a Prospective Multidimensional cOhort) Study Group. Role of Normalized T-Cell Subsets in Predicting Comorbidities in a Large Cohort of Geriatric HIV-infected Patient. **J Acquir Immune Defic Syndr** 2017.
164. Mornese Pinna S, Scarvaglieri E, Milia MG, Imperiale D, Ghisetti V, Audagnotto S, Prochet A, Lipani F, Bonora S, Di Perri G, [Calcagno A](#). Detectable cerebrospinal fluid JCV DNA in late-presenting HIV-positive patients: beyond progressive multifocal leukoencephalopathy? **J Neurovirol** 2017.
165. Nozza S, Malagoli A, Maia L, [Calcagno A](#), Focà E, De Socio G, Piconi S, Orofino G, Cattelan AM, Celesia BM, Gervasi E, Guaraldi G; GEPO Study Group. Antiretroviral therapy in geriatric HIV patients: the GEPO cohort study. **J Antimicrob Chemother** 2017.
166. Allegra S, Fatiguso G, [Calcagno A](#), Baietto L, Motta I, Favata F, Cusato J, Bonora S, Di Perri G, D'Avolio A. Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics. **Pharmacogenomics** 2017.
167. [Calcagno A](#), Lucchini A, Caracciolo D, Balbiano R, Bracchi M, Sordella F, Gregori G, Lipani F, Audagnotto S, Chiriotto M, Cavaglià G, Ghisetti V, Di Perri G, Bonora S. High Incidence of Infections in HIV-positive Patients Treated for Lymphoproliferative Disorders. **Curr HIV Res** 2017.
168. [Calcagno A](#), Pagani N, Ariaudo A, Arduino G, Carcieri C, D'Avolio A, Marinaro L, Tettoni MC, Trentini L, Di Perri G, Bonora S. Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure. **J Antimicrob Chemother** 2017.
169. Biagini R, Montrucchio C, [Calcagno A](#), Trentini L, Tettoni MC, Alcantarini C, Barco A, Trentalange A, Milesi M, Ferrara M, Bertucci R, Di Perri G, Bonora S. Geriatrics in HIV infection: multimorbidity, polypharmacy and primary prevention in patients above 65 years). **Journal of HIV and Ageing**. 2017. *Not Impacted*
170. Motta I, Alice T, Romito A, Ferrara M, Ecclesia S, Imperiale D, Ghisetti V, Di Perri G, Bonora S, [Calcagno A](#). Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia. **Antivir Ther** 2017.
171. Motta I, [Calcagno A](#), Baietto L, Bigliano P, Costa C, Baruffi K, Fatiguso G, D'Avolio A, Di Perri G, Bonora S. Pharmacokinetics of first-line antitubercular drugs in plasma and PBMCs. **Br J Clin Pharmacol** 2017.
172. Montrucchio C, Biagini R, Alcantarini C, [Calcagno A](#), Barco A, Ferrara M, Milesi M, Costa C, Trentalange A, Trunfio M, Tettoni MC, Grosso Marra W, D'Ascenzo F, Ballocca F, Lonni E, Gili S, Vai D, Imperiale D, Gaita F, Bonora S, Di Perri G. Cardiovascular risk and neurocognitive deficits in HIV-positive individuals. **Infectious Diseases & Tropical Medicine** 2017. *Not Impacted*.
173. [Calcagno A](#), Di Perri G, Bonora S. Treating HIV Infection in the Central Nervous System. **Drugs** 2017.
174. Armenia D, Di Carlo D, [Calcagno A](#), Vendemiati G, Forbici F, Bertoli A, Berno G, Carta S, Continenza F, Fedele V, Bellagamba R, Cicalini S, Ammassari A, Libertone R, Zaccarelli M, Ghisetti V, Andreoni M, Ceccherini-Silberstein F, Bonora S, Di Perri G, Antinori A, Perno CF, Santoro MM. Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen. **J Antimicrob Chemother** 2016.
175. Marinaro L, [Calcagno A](#), Ripamonti D, Cenderello G, Pirriatore V, Trentini L, Salassa B, Bramato C, Orofino G, D'Avolio A, Rizzi M, Di Perri G, Rusconi S, Bonora S. Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting. **J Clin Virol** 2016.
176. Guaraldi G, Menozzi M, Zona S, [Calcagno A](#), Silva AR, Santoro A, Malagoli A, Dolci G, Mussi C, Mussini C, Cesari M, Khoo SH. Impact of polypharmacy on antiretroviral prescription in people living with HIV. **J Antimicrob Chemother** 2016.
177. [Calcagno A](#), Romito A, Atzori C, Ghisetti V, Cardellino C, Audagnotto S, Scarvaglieri E, Lipani F, Imperiale D, Di Perri G, Bonora S. Blood Brain Barrier Impairment in HIV-Positive Naïve and Effectively Treated Patients: Immune Activation Versus Astrocytosis. **J Neuroimmune Pharmacol** 2016.
178. Sanfilippo C, Nunnari G, [Calcagno A](#), Malaguarnera L, Blennow K, Zetterberg H, Di Rosa M. The chitinases expression is related to Simian Immunodeficiency Virus Encephalitis (SIVE) and in HIV encephalitis (HIVE). **Virus Res** 2016.
179. [Calcagno A](#), Cusato J, D'Avolio A, Bonora S. Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs. **Clin Pharmacokinet** 2016.
180. Gili S, Mancone M, Ballocca F, Grosso Marra W, [Calcagno A](#), D'Ettore G, Cannillo M, D'Ascenzo F, Orofino G, Marruncheddu L, Lonni E, Cinque A, Vullo F, Ceccarelli G, Vilardi I, Sardella G, Vullo V, Moretti C, Fedele F, Bonora S, Gaita F. Prevalence and predictors of long corrected QT interval in HIV-positive patients: a multicenter study. **J Cardiovasc Med (Hagerstown)** 2016.
181. Ruggiero T, Burdino E, [Calcagno A](#), Bonora S, Boglione L, Di Perri G, Ghisetti V. HCV NS3 naturally occurring variants in HIV/HCV coinfecting DAA-naïve patients: consideration for HCV genotyping resistance testing. **Infection** 2016.
182. Focà E, Nunnari G, [Calcagno A](#). The good, the bad and the ugly: Determinants of antiretroviral-associated toxicities. **Future Virology** 2016.
183. Patti F, [Calcagno A](#), Simiele M, Bonasso M, Di Perri G, D'Avolio A, Bonora S. Pharmacokinetics of an antiretroviral regimen in a patient unable to swallow solid oral dosage forms. **Am J Health Syst Pharm** 2016.
184. [Calcagno A](#), Di Perri G, Bonora S. What do we know about tailoring treatment with tenofovir? **Pharmacogenomics** 2016.

185. [Calcagno A](#), Simiele M, Motta I, Mornese Pinna S, Bertucci R, D'Avolio A, Di Perri G, Bonora S. Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients. **AIDS Res Hum Retroviruses** 2016.
186. Ballocca F, Gili S, D'Ascenzo F, Marra WG, Cannillo M, [Calcagno A](#), Bonora S, Flammer A, Coppola J, Moretti C, Gaita F. HIV Infection and Primary Prevention of Cardiovascular Disease: Lights and Shadows in the HAART Era. **Prog Cardiovasc Dis** 2016.
187. Trentalange A, [Calcagno A](#), Ghisetti V, Atzori C, Busolli P, Bonora S, Imperiale D. Clearance of cerebrospinal fluid JCV DNA with mirtazapine in a patient with progressive multifocal leukoencephalopathy and sarcoidosis. **Antivir Ther** 2016.
188. Gili S, Grosso Marra W, D'Ascenzo F, Lonni E, [Calcagno A](#), Cannillo M, Ballocca F, Cerrato E, Pianelli M, Barbero U, Mancone M, DiNicolantonio JJ, Lavie CJ, Omedè P, Montefusco A, Bonora S, Gasparini M, Biondi-Zoccai G, Moretti C, Gaita F. Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis. **Eur Heart J** 2016.
189. Lucchini A, Lipani F, Costa C, Scarvaglieri M, Balbiano R, Carosella S, [Calcagno A](#), Audagnotto S, Barbui AM, Brossa S, Ghisetti V, Dal Conte I, Caramello P, Di Perri G. Louseborne Relapsing Fever among East African Refugees, Italy, 2015. **Emerg Infect Dis** 2016.
190. Cusato J, Tomasello C, Simiele M, [Calcagno A](#), Bonora S, Marinaro L, Leggieri A, Allegra S, Di Perri G, D'Avolio A. Efavirenz pharmacogenetics in a cohort of Italian patients. **Int J Antimicrob Agents** 2015.
191. Motta I, [Calcagno A](#), Baietto L, D'Avolio A, De Rosa FG, Bonora S. A probable drug-to-drug interaction between voriconazole and haloperidol in a slow CYP2C9 metabolizer. **Infez Med** 2015. *Not impacted*.
192. Bonora S, [Calcagno A](#), Trentalange A, Perri GD. Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults. **Expert Opin Pharmacother** 2015.
193. Fatiguso G, Allegra S, [Calcagno A](#), Baietto L, Motta I, Favata F, Cusato J, Bonora S, Perri GD, D'Avolio A. Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study. **Int J Pharm** 2015.
194. [Calcagno A](#), Rostagno R, Arnaudo I, Zanusso G, Bonora S, Lucchini A, Maiello A, Dal Conte I, Meoli I, Ferrari S, Monaco S, Rizzuto N, Di Perri G. CSF 14-3-3 protein and its ζ isoform are prognostic markers in HIV positive patients with CNS disease. **Infectious Diseases & Tropical Medicine** 2015. *Not Impacted*.
195. [Calcagno A](#), Cusato J, Marinaro L, Simiele M, Lucchiarini M, Alcantarini C, Tettoni MC, Trentini L, Mengozzi G, D'Avolio A, Di Perri G, Bonora S. Tenofovir clearance is reduced in hiv-positive patients with subclinical tubular impairment. **AIDS** 2016.
196. Livelli A, Orofino GC, [Calcagno A](#), Farenga M, Penoncelli D, Guastavigna M, Carosella S, Caramello P, Pia L. Evaluation of a Cognitive Rehabilitation Protocol in HIV Patients with Associated Neurocognitive Disorders: Efficacy and Stability Over Time. **Front Behav Neurosci** 2015.
197. Andreoni M, Marcotullio S, Puro V, De Carli G, Tambussi G, Nozza S, Gori A, Rusconi S, Santoro MM, Clementi M, Perno CF, d'Arminio Monforte A, Maggiolo F, Castagna A, De Luca A, Galli M, Giacomelli A, Borderi M, Guaraldi G, [Calcagno A](#), Di Perri G, Bonora S, Mussini C, Di Biagio A, Puoti M, Bruno R, Zuccaro V, Antinori A, Cinque P, Croce D, Restelli U, Rizzardini G, Lazzarin A. An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaimProject. **New Microbiol** 2015.
198. [Calcagno A](#), Cusato J, Marinaro L, Trentini L, Alcantarini C, Mussa M, Simiele M, D'Avolio A, Di Perri G, Bonora S. Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines. **Pharmacogenomics J** 2015.
199. [Calcagno A](#), Montrucchio C, Capetti A, Guaraldi G, Cenderello G, Calza L, Lanzafame M, Marinaro L, Tettoni MC, Trentini L, D'Avolio A, Di Perri G, Bonora S. Raltegravir plus Nevirapine as Maintenance Antiretroviral Therapy in HIV-positive Patients: Safety, Efficacy and Pharmacokinetics. **Curr HIV Res** 2015.
200. [Calcagno A](#), Trentalange A, Simiele M, Marinaro L, Patti F, Tettoni MC, Trentini L, Di Perri G, D'Avolio A, Bonora S. Rilpivirine Pharmacokinetics in 3 HIV-Positive Patients With Liver Cirrhosis Concomitantly Receiving Pantoprazole. **Ther Drug Monit** 2015.
201. [Calcagno A](#), Atzori C, Romito A, Vai D, Audagnotto S, Stella ML, Montrucchio C, Imperiale D, Di Perri G, Bonora S. Blood brain barrier impairment is associated with cerebrospinal fluid markers of neuronal damage in HIV-positive patients. **J Neurovirol** 2015.
202. Siccardi M, Olagunju A, Simiele M, D'Avolio A, [Calcagno A](#), Di Perri G, Bonora S, Owen A. Class-specific relative genetic contribution for key antiretroviral drugs. **J Antimicrob Chemother** 2015.
203. Bonora S, Rusconi S, [Calcagno A](#), Bracchi M, Viganò O, Cusato J, Lanzafame M, Trentalange A, Marinaro L, Siccardi M, D'Avolio A, Galli M, Di Perri G. Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study). **J Antimicrob Chemother** 2015.
204. [Calcagno A](#), Motta I, Ghisetti V, Lo Re S, Alice T, Marinaro L, Milia MG, Tettoni MC, Trentini L, Orofino G, Salassa B, Di Perri G, Bonora S. HIV-1 Very Low Level Viremia is Associated with Virological Failure in HAART-treated Patients. **AIDS Res Hum Retroviruses** 2015.
205. [Calcagno A](#), D'Avolio A, Bonora S. Pharmacokinetic and pharmacodynamic evaluation of Raltegravir and Experience from Clinical Trials in HIV-positive Patients. **Expert Opinion On Drug Metabolism and Toxicology** 2015.
206. Baietto L, [Calcagno A](#), Motta I, Baruffi K, Poretti V, Di Perri G, Bonora S, D'Avolio A. A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs. **J Antimicrob Chemother** 2015.
207. Simiele M, Carcieri C, De Nicolò A, Ariando A, Sciandra M, [Calcagno A](#), Bonora S, Di Perri G, D'Avolio A. A LC-MS method to quantify tenofovir urinary concentrations in treated patients. **J Pharm Biomed Anal** 2015.
208. [Calcagno A](#), Nozza S, Muss C, Celestia BM, Carli F, Piconi S, De Socio GV, Cattelan AM, Orofino G, Ripamonti D, Riva A, Di Perri G. Ageing with HIV: a multidisciplinary review. **Infection** 2015.
209. Cerrato E, [Calcagno A](#), D'Ascenzo F, Biondi-Zoccai G, Mancone M, Grosso Marra W, Demarie D, Omedè P, Abbate A, Bonora S, DiNicolantonio JJ, Estrada V, Escaned J, Moretti C, Gaita F. Cardiovascular disease in HIV patients: from bench to bedside and backwards. **Open Heart** 2015. *Not Impacted*.
210. D'Ascenzo F, Cerrato E, [Calcagno A](#), Grossomarra W, Ballocca F, Omedè P, Montefusco A, Veglia S, Barbero U, Gili S, Cannillo M, Pianelli M, Mistretta E, Raviola A, Salera D, Garabellò D, Mancone M, Estrada V, Escaned J, De Marie D, Abbate A, Bonora S, Zoccai GB, Moretti C, Gaita F. High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: A meta-analysis. **Atherosclerosis** 2015.
211. Ghisetti V, [Calcagno A](#), Burdino E, Orofino G, Bonora S. Acute HIV infection: Improved algorithms for HIV testing. **J Clin Virol** 2015.
212. [Calcagno A](#), Motta I, Milia M, Rostagno R, Simiele M, Libanore V, Fontana S, D'Avolio A, Ghisetti V, Di Perri G, Bonora S. Dried Plasma/Blood Spots for Monitoring Antiretroviral Treatment Efficacy and Pharmacokinetics: a Cross-sectional Study in Rural Burundi. **Br J Clin Pharmacol** 2015.

213. [Calcagno A](#), Simiele M, Alberione MC, Bracchi M, Marinaro L, Ecclesia S, Di Perri G, D'Avolio A and Bonora S. Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-positive Patients are Associated with Compartmental Viral Control. **Clin Infect Dis** 2015.
214. Baietto L, D'Avolio A, Cusato J, Pace S, [Calcagno A](#), Motta I, Corcione S, Di Perri G, De Rosa FG. Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients. **J Antimicrob Chemother** 2014.
215. [Calcagno A](#), Di Perri G, Bonora S. Pharmacokinetics and Pharmacodynamics of Antiretrovirals in the Central Nervous System. **Clinical Pharmacokinetics** 2014.
216. Trentalange A, [Calcagno A](#), Raviolo S, Prochet A, Audagnotto S, Ghisetti V, Di Perri G and Bonora S. Cytomegalovirus Central Nervous System Compartmentalization in a Patient Presenting with AIDS. **Antiviral therapy** 2014.
217. Bonora S, [Calcagno A](#), Viganò O, Bigliano P, Marinaro L, Colella E, Orofino G, Trentini L, Tettoni MC, D'Avolio A, Mercadante S, Galli M, Di Perri G and Rusconi S. Efficacy, Tolerability and Virological Consequences of Long-term Use of Unboosted Atazanavir plus 2 NRTIs in HIV-infected Patients. **Current HIV Research** 2014.
218. [Calcagno A](#), Baietto L, Pagani N, Simiele M, Audagnotto S, D'Avolio A, De Rosa FG, Di Perri G and Bonora S. Voriconazole and Atazanavir: a CYP 2C19-dependant Manageable Drug to Drug Interaction. **Pharmacogenomics** 2014.
219. Cannillo M, D'Ascenzo F, Grosso Marra W, Cerrato E, [Calcagno A](#), Omedè P, Bonora S, Mancone M, Vizza D, DiNicolantonio JJ, Pianelli M, Barbero U, Gili S, Annone U, Raviola A, Salera D, Mistretta E, Vilardi I, Colaci C, Abbate A, Zoccai GB, Moretti C, Gaita F. Heart failure in patients with human immunodeficiency virus: a review of the literature. **J Cardiovasc Med (Hagerstown)** 2014.
220. Lanzafame M, Bonora S, Lattuada E, [Calcagno A](#), Di Perri G, Concia E. Disappearance of renal stones in a HIV-1-infected patient after reduction of atazanavir dose. **AIDS Res Hum Retroviruses** 2014.
221. D'Avolio A, Carcieri C, Cusato J, Simiele M, [Calcagno A](#), Allegra S, Sciandra M, Trentini L, Di Perri G, Bonora S. Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. **J Antimicrob Chemother** 2014.
222. D'Ascenzo F, Quadri G, Cerrato E, [Calcagno A](#), Omedè P, Grosso Marra W, Abbate A, Bonora S, Biondi Zoccai G, Moretti C, Gaita F. A meta-analysis investigating incidence and features of stroke in HIV-infected patients in the highly active antiretroviral therapy era. **J Cardiovasc Med (Hagerstown)** 2014.
223. [Calcagno A](#), Alberione MC, Romito A, Imperiale D, Ghisetti V, Audagnotto S, Lipani F, Raviolo S, Di Perri G, Bonora S. Prevalence and predictors of blood-brain barrier damage in the HAART era. **J Neurovirol.** 2014.
224. D'Ascenzo F, Cerrato E, Appleton D, Moretti C, [Calcagno A](#), Abouzaki N, Vetrovec G, Lhermusier T, Carrie D, Das Neves B, Escaned J, Cassese S, Kastrati A, Chinaglia A, Belli R, Capodanno D, Tamburino C, Santilli F, Parodi G, Vachiat A, Manga P, Vignali L, Mancone M, Sardella G, Fedele F, DiNicolantonio JJ, Omedè P, Bonora S, Gaita F, Abbate A, Biondi Zoccai G. Prognostic Indicators for Recurrent Thrombotic Events in HIV-infected Patients With Acute Coronary Syndromes: Use of Registry Data From 12 sites in Europe, South Africa and the United States. **Thrombosis Research** 2014.
225. [Calcagno A](#), Marinaro L, Nozza S, Aldieri C, Carbone A, Ghisetti V, Trentalange A, D'Avolio A, Castagna A, Di Perri G and Bonora S. Etravirine Plasma Exposure is Associated with Virological Efficacy in Treatment-experienced HIV-positive Patients. **Antiviral Res** 2014.
226. [Calcagno A](#), Lamorde M, D'Avolio A and Bonora S. Personalizing HIV Therapeutics in Resource-Limited Rural Communities: Lessons Learned From the Use of New Tools in Africa. **Current Pharmacogenomics and Personalized Medicine** 2014. *Not Impacted*
227. De Nicolò A, Simiele M, [Calcagno A](#), Abdi AM, Bonora S, Di Perri G and D'Avolio A. Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitors regimens. **Antimicrob Agents Chemother** 2014.
228. [Calcagno A](#), Nozza S, Simiele M, Milia MG, Chiappetta S, D'Avolio A, Ghisetti V, Lazzarin A, Di Perri G, Bonora S. Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients. **J Antimicrob Chemother** 2014.
229. De Nicolò A, Simiele M, [Calcagno A](#), Mohamed Abdi A, Bonora S, Di Perri G, D'Avolio A. Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitors regimens. **Antimicrob Agents Chemother** 2014.
230. Corcione S, Cardellino CS, [Calcagno A](#), Fossati L, Costa C, Cavallo R, Di Perri G, De Rosa FG. Health-care Associated KPC-BSI: The Time Has Come. **Clin Infect Dis** 2014.
231. Salizzoni S, D'Ascenzo F, Moretti C, Bonora S, [Calcagno A](#), Omedè P, Montrucchio C, Cerrato E, Colaci C, Sheiban I, Marra S, Rinaldi M, Gaita F. Transcatheter aortic valve implantation in a 54-year-old patient with aggressive HIV. **World J Clin Cases** 2014. *Not Impacted*
232. Marchetti G, Cozzi-Lepri A, Tincati C, [Calcagno A](#), Ceccherini-Silberstein F, De Luca A, Antinori A, Castagna A, Puoti M, Monforte Ad; Ico Foundation Study Group. Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Ico Foundation study. **BMC Infect Dis** 2014.
233. Nozza S, Bigoloni A, [Calcagno A](#), Galli L, Pignataro AR, D'Avolio A, Carbone A, Ripa M, Bonora S, Lazzarin A, Castagna A. Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. **J Antimicrob Chemother** 2014.
234. De Francia S, D'Avolio A, Ariaudo A, Pirro E, Piccione F, Simiele M, Fava C, [Calcagno A](#), Di Perri G, Saglio G. Plasma and Intracellular Imatinib Concentrations in Patients With Chronic Myeloid Leukemia. **Ther Drug Monit** 2014.
235. [Calcagno A](#), D'Avolio A, Di Perri G and Bonora S. Comment on "Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral therapy is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid". **J Acquir Immune Defic Syndr** 2013.
236. [Calcagno A](#), Cusato J, Simiele M, et al. High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. **J Antimicrob Chemother** 2014.
237. Ruggiero T, De Rosa F, Cerutti F, Pagani N, Alice T, Stella ML, Milia MG, [Calcagno A](#), Burdino E, Gregori G, Urbino R, Di Perri G, Ranieri MV, Ghisetti V. A(H1N1)pdm09 hemagglutinin D222G and D222N variants are frequently harbored by patients requiring extracorporeal membrane oxygenation and advanced respiratory assistance for severe A(H1N1)pdm09 infection. **Influenza Other Respi Viruses** 2013.
238. [Calcagno A](#), Baietto L, Pagani N, et al. Pharmacokinetics of caspofungin increased dosage in a patient on rifampin-containing anti-tubercular treatment. **Scand J Infect Dis** 2013.
239. D'Avolio A, Cusato J, [Calcagno A](#) and Di Perri G. Estimating Ribavirin plasma exposure: genetics or therapeutic drug monitoring? **J Hepatol** 2013.

240. [Calcagno A](#), Trentini L, Marinaro L, Montrucchio C, D'Avolio A, Ghisetti V, Di Perri G, Bonora S. Transplacental passage of etravirine and maraviroc in a multidrug-experienced HIV-infected woman failing on darunavir-based HAART in late pregnancy. **J Antimicrob Chemother** 2013.
241. [Calcagno A](#), Nozza S, de Requena DG, Galli A, D'Avolio A, Simiele M, Chiappetta S, Di Perri G, Lazzarin A, Bonora S. Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naïve patients. **J Antimicrob Chemother** 2013.
242. [Calcagno A](#), Boglione L, De Rosa FG, Di Perri G, Bonora S. Elimination Half-Life May Explain the Relative Efficacy of Boceprevir and Telaprevir in the Treatment of Hepatitis C Virus Genotype 1. **Clin Infect Dis** 2013.
243. [Calcagno A](#), Gonzalez de Requena D, Simiele M, D'Avolio A, Tettoni M, Salassa B, Orofino G, Bramato C, Libanore V, Motta I, Bigliano P, Orsucci E, Di Perri G, Bonora S. Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-sectional Study in HIV-positive Patients with Normal Renal Function. **Antimicrob Agents Chemother** 2013.
244. Santoro MM, Armenia D, Alteri C, Flandre P, [Calcagno A](#), Santoro M, Gori C, Fabeni L, Bellagamba R, Borghi V, Forbici F, Latini A, Palamara G, Libertone R, Tozzi V, Boumis E, Tommasi C, Pinnetti C, Ammassari A, Nicastri E, Buonominì A, Svicher V, Andreoni M, Narciso P, Mussini C, Antinori A, Ceccherini-Silberstein F, Di Perri G, Perno CF. Impact of pre-therapy viral load on virological response to modern first-line HAART. **Antivir Ther** 2013.
245. Cerrato E, D'Ascenzo F, Biondi-Zoccai G, [Calcagno A](#), Frea S, Grosso Marra W, Castagno D, Omedè P, Quadri G, Sciuto F, Presutti D, Frati G, Bonora S, Moretti C, Gaita F. Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era. **Eur Heart J** 2013.
246. [Calcagno A](#), Tettoni MC, Simiele M, Trentini L, Montrucchio C, D'Avolio A, Di Perri G, Bonora S. Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors. **J Antimicrob Chemother** 2013.
247. Rekić D, Röshammar D, Bergstrand M, Tarning J, [Calcagno A](#), D'Avolio A, Ormaasen V, Vigan M, Barrail-Tran A, Ashton M, Gisslén M, Abelö A. External Validation of the Bilirubin-Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients. **AAPS J** 2013.
248. D'Avolio A, Simiele M, [Calcagno A](#), Siccardi M, Larovere G, Agati S, Baietto L, Cusato J, Tettoni M, Sciandra M, Trentini L, Di Perri G, Bonora S. Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. **J Antimicrob Chemother** 2012.
249. D'Avolio A, Ciancio A, Siccardi M, Smedile A, Simiele M, Cusato J, Baietto L, Marucco DA, Cariti G, [Calcagno A](#), Gonzalez de Requena D, Sciandra M, Troshina G, Caviglia GP, Bonora S, Rizzetto M, Di Perri G. Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment. **Ther Drug Monit** 2012.
250. [Calcagno A](#), Rostagno R, Di Perri G. Anti-CD20 antibody therapy for B-cell lymphomas. **N Engl J Med** 2012.
251. Bibas M, Lorenzini P, Cozzi-Lepri A, [Calcagno A](#), di Giambenedetto S, Costantini A, Castagna A, Manfrin V, Monforte AD, Antinori A; for the ICONA Cohort Study Group. Polyclonal serum free light chains elevation in HIV-infected patients. **AIDS** 2012.
252. [Calcagno A](#), Yilmaz A, Cusato J, Simiele M, Bertucci R, Siccardi M, Marinaro L, D'Avolio A, Di Perri G, Bonora S. Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. **AIDS**. 2012.
253. D'Avolio A, De Nicolò A, Simiele M, Turini S, Agnesod D, Boglione L, Cusato J, Baietto L, Cariti G, [Calcagno A](#), Sciandra M, Di Perri G, Bonora S. Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients. **J Pharm Biomed Anal**. 2012.
254. [Calcagno A](#), D'Avolio A, Simiele M, Cusato J, Rostagno R, Libanore V, Baietto L, Siccardi M, Bonora S and Di Perri G. Influence of CYP2B6 and ABCB1 SNPs on Nevirapine Plasma Concentrations in Burundese HIV-positive Patients Using Dried Sample Spots Devices. **British Journal of Clinical Pharmacology** 2012.
255. D'Avolio A, Ciancio A, Siccardi M, Smedile A, Baietto L, Simiele M, Aguilar Marucco D, Cariti G, [Calcagno A](#), Gonzalez de Requena D, Sciandra M, Cusato J, Troshina M, Bonora S, Rizzetto M and Di Perri G. ITPA polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associated anaemia in patients under standard anti-HCV treatment. **Therapeutic Drug Monitoring** 2012.
256. Bonora S, [Calcagno A](#), Cometto C, Fontana S, Aguilar D, D'Avolio A, Gonzalez de Requena D, Maiello A, Dal Conte I, Lucchini A and Di Perri G. Short Term Additional Enfuvirtide Therapy is Associated with a Greater Immunological Recovery in HIV Very Late Presenters: a Controlled Pilot Study. **Infection** 2012.
257. Siccardi M, D'Avolio A, Rodriguez-Novoa S, Simiele M, Baietto L, [Calcagno A](#), Moss D, Back D, Owen A, Bonora S and Di Perri G. Intra and inter patient pharmacokinetic variability of raltegravir in the clinical setting. **Therapeutic Drug Monitoring** 2012.
258. D'Avolio A, Ciancio A, Siccardi M, Baietto L, Simiele M, Cariti G, [Calcagno A](#), Smedile A, Cusato J, Bonora S, Rizzetto M and Di Perri G. Ribavirin Pharmacokinetics and IL28 plus CYP27B1 SNPs as predictors of response to Peg-IFN/RBV treatment in HCV ¼ infected patients. **Hepatology** 2011.
259. [Calcagno A](#), Bonora S, Simiele M, Rostagno R, Tettoni MC, Bonasso M, Romito A, Imperiale D, D'Avolio A and Di Perri G. Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage. **AIDS** 2011.
260. [Calcagno A](#), Nozza S, Bonora S, Castagna A, Gonzalez de Requena D, D'Avolio A, Lazzarin A and Di Perri G. Pharmacokinetics of the Raltegravir/Maraviroc/Etravirine Combination. **J Antimicrob Chemother** 2011.
261. Bonora S, Gonzalez de Requena D, D'Avolio A, [Calcagno A](#), Tettoni MC, Siccardi M, Baietto L, Simiele M, Trentini L, Di Perri G. Pharmacokinetics of switching unboosted Atazanavir co-administered with Tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. **Antiviral Therapy** 2011.
262. Gonzalez de Requena D, Bonora S, Viganò O, [Calcagno A](#), Cometto C, D'Avolio A, Baietto L, Ghisetti V, Magnani S, Ferramosca S, Vitiello P, Galli M, Rusconi S, Di Perri G. Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. **J Antimicrob Chemother** 2011.
263. [Calcagno A](#), Baietto L, De Rosa FG, Tettoni MC, Libanore V, Bertucci R, D'Avolio A, Di Perri G. Posaconazole cerebrospinal concentrations in an HIV-infected patient with brain mucormycosis. **J Antimicrob Chemother** 2011.
264. Lanzafame M, Bonora S, Lattuada E, [Calcagno A](#), Vento S. A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients. **Braz J Infect Dis** 2011.
265. Siccardi M, D'Avolio A, Nozza S, Simiele M, Baietto L, Stefani FR, Moss D, Kwan W, Castagna A, Lazzarin A, [Calcagno A](#), Bonora S, Back D, Di Perri G, Owen A. Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLC01B1 521C>T polymorphism. **Pharmacogenet Genomics** 2010.

266. Calcagno A, Rostagno R, Audagnotto S, D'Avolio A, Bonora S, Ghisetti V, Di Perri G. Is peritoneal fluid a sanctuary site for HIV? **J Antimicrob Chemother** 2010.
267. Calcagno A, Bonora S, D'Avolio A, Siccardi M, Simiele M, Chiesa M, Gonzalez de Requena D, Di Perri G. Raltegravir penetration in seminal plasma of healthy volunteers. **Antimicrob Agents Chemother** 2010.
268. Calcagno A, Bonora S, Bertucci R, Lucchini A, D'Avolio A, Di Perri G. Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients. **AIDS** 2010.
269. Lanzafranco M, Hill A, Lattuada E, Calcagno A, Bonora S. Raltegravir: is a 400 mg once-daily dose enough? **J Antimicrob Chemother** 2010.
270. Calcagno A, Bonora S, Tettoni MC, D'Avolio A, Lanzafranco M, Penco G, Di Perri G. Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting. **J Acquir Immune Defic Syndr** 2009.
271. Bonora S, Calcagno A, Di Perri G. HIV infection: treatment of naïve patients. **Infez Med** 2009. *Not Impacted*.
272. Bonora S, Nicastri E, Calcagno A, Gonzalez de Requena D, D'Ettorre G, Sarmati L, Palmisano L, Vullo V, Di Perri G, Andreoni M. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation. **J Med Virol** 2009.
273. Bonora S, Mondo A, Trentini L, Calcagno A, Lucchini A, Di Perri G. Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contraindications or intolerance to rifamycins. **Journal of Infection** 2008.
274. González de Requena D, Bonora S, Castagna A, Hasson H, Marucco Aguilar D, D'Avolio A, Sciandra M, Trentini L, Calcagno A, Lazzarin A, Di Perri G. Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients. **J Antimicrob Chemother** 2008.
275. González de Requena DG, Bonora S, Calcagno A, D'Avolio A, Siccardi M, Fontana S, Milia MG, Sciandra M, Garazzino S, Di Garbo A, Baietto L, Trentini L, Di Perri G. Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens. **Antimicrob Agents Chemother** 2008.
276. Bonora S, Calcagno A, Fontana S, D'Avolio A, Siccardi M, Gobbi F, Di Perri G. Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject. **Clin Infect Dis** 2007.
277. Aguilar Marucco D, Veronese L, de Requena DG, Bonora S, Calcagno A, Cavecchia I, Sinicco A, De Rosa FG, Cariti G, Di Perri G. Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus. **J Antimicrob Chemother** 2007.
278. González de Requena D, Calcagno A, Bonora S, Ladetto L, D'Avolio A, Sciandra M, Siccardi M, Bargiacchi O, Sinicco A, Di Perri G. Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide. **AIDS** 2006.
279. Garazzino S, Tettoni M, Calcagno A, D'Avolio A, Bonora S, Di Perri G. Ritonavir-dependent fluconazole boosting of nelfinavir: a report of three cases. **J Antimicrob Chemother** 2006.
280. Bonora S, Calcagno A, Gonzalez de Requena D, Bargiacchi O, Di Perri G. Clinical pharmacology of nucleoside and nucleotide reverse transcriptase inhibitors. **Infez Med** 2006. *Not Impacted*.

Indexes Published articles: 280
 Citations (Scopus): 4517
 H-index (Scopus): 31
 H-index (Google Scholar): 39
 i10-index (Google Scholar): 173

Lectures at National and International Conferences

I have gathered experience in speaking and chairing at national and international conferences since 2008: I have been public speaking in Italian, English, and Spanish. The topics I have been covering are HIV, tuberculosis, NTM, central nervous system and hospital-acquired infections.

Books

I Co-wrote the chapter “*Staphylococcus aureus* meticillino-resistente” in the book “Infezioni di difficile trattamento in terapia intensiva – Approccio Clinico”, 2024, Minerva Medica. Editors: Luca Brazzi and Gioria Montrucchio. ISBN: 9788855322522.

I Participated in the writing of the Chapter “Clinical Treatment Options and Randomized Clinical Trials for Neurocognitive Complications of HIV Infection: Combination Antiretroviral Therapy, Central Nervous System Penetration Effectiveness, and Adjuvants” in the book “Neurocognitive Complications of HIV-Infection” Springer. Editors: Lucette A. Cysique and Sean B. Rourke ISBN: 978-3-030-80758-0.

I Co-Wrote the chapter “Aging with HIV and Oxidative stress”, in the book “HIV/AIDS, Oxidative Stress and Dietary Antioxidants” Elsevier. Editors: Victor Preedy Ronald Watson. ISBN: 9780128098530.

I Wrote the chapter “Antiretroviral Drug Penetration into the CNS Compartment” in the printed and online “Encyclopedia of AIDS” Springer. Editors: Thomas J. Hope, Mario Stevenson, Douglas Richman. ISBN: 978-1-4614-9610-6 (Online)

I am one of the authors of the chapter “Natural History of HIV Infection and Evolution of Antiretroviral Therapy” in the book “Cardiovascular Disease in AIDS”, Springer-verlag Italia S.r.l., 2008, Barbaro G, Boccara F and Skolnik PR.

I Participated in the writing of the chapter “Donovanosis” in the book “Infezioni Genitali: Aspetti patogenetici, clinici e diagnostici”, Latino MA, Magliano E, AMCLI, Milano, 2009.

Reviewer activity

I am acting as a reviewer for several national and international scientific journals and for national and international grant applications.

**Spoken
Languages**

Good knowledge of English and Spanish, basic knowledge of French. Italian as mother tongue.

Torino, Italy; October 3rd 2025
CALCAGNO ANDREA



*Autorizzo il trattamento dei miei dati personali ai sensi dell'art. 13 d. lgs. 30 giugno 2003 n°196-
“Codice in materia di protezione dei dati personali” e dell'art. 13 GDPR 679/16 – “Regolamento
europeo sulla protezione dei dati personali*

Torino, Italy; October 3rd 2025
CALCAGNO ANDREA

